

# Cancer immunotherapy via dendritic cells

Nature Reviews Cancer

12, 265-277

DOI: [10.1038/nrc3258](https://doi.org/10.1038/nrc3258)

Citation Report

#	ARTICLE	IF	CITATIONS
2	mRNA as a Versatile Tool for Exogenous Protein Expression. <i>Current Gene Therapy</i> , 2012, 12, 347-361.	0.9	57
3	Inefficient boosting of antitumor CD8+T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. <i>Oncolmmunology</i> , 2012, 1, 1507-1516.	2.1	6
4	A vaccine in renal cell carcinoma: are we nearing reality?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1503-1505.	1.1	3
5	Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. <i>Oncolmmunology</i> , 2012, 1, 1655-1657.	2.1	38
6	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1557-1576.	2.1	110
7	Making Dendritic Cells that Turn Immune Responses Off. <i>Human Gene Therapy</i> , 2012, 23, ix-xi.	1.4	0
8	Regulatory dendritic cells: there is more than just immune activation. <i>Frontiers in Immunology</i> , 2012, 3, 274.	2.2	187
9	Science to Practice: Genetic Engineering Meets Cell Trackingâ€”A Promising Approach for Cell-based Therapies?. <i>Radiology</i> , 2012, 265, 1-3.	3.6	1
10	Dendritic cell-based immunotherapy in mesothelioma. <i>Immunotherapy</i> , 2012, 4, 1011-1022.	1.0	10
11	The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. <i>Immunobiology</i> , 2012, 217, 1225-1232.	0.8	21
12	Dendritic cell vaccination in acute myeloid leukemia. <i>Cytotherapy</i> , 2012, 14, 647-656.	0.3	49
13	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. <i>Cellular Immunology</i> , 2012, 278, 21-26.	1.4	19
14	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1111-1134.	2.1	152
15	Elucidating the regulation of T cell subsets. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1255-1260.	1.8	11
16	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 1323-1343.	2.1	203
17	Mesenchymal stem cells as a novel vaccine platform. <i>Frontiers in Cellular and Infection Microbiology</i> , 2012, 2, 140.	1.8	21
18	Dendritic Cells Interactions with the Immune System â€” Implications for Vaccine Development. , 0, , .		1
19	Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy. <i>Journal of Translational Medicine</i> , 2013, 11, 166.	1.8	18

#	ARTICLE	IF	CITATIONS
20	Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 46-51.	1.8	24
21	Rapamycin and omega-1: mTOR-dependent and -independent Th2 skewing by human dendritic cells. <i>Immunology and Cell Biology</i> , 2013, 91, 486-489.	1.0	43
22	Human dendritic cell subsets in vaccination. <i>Current Opinion in Immunology</i> , 2013, 25, 396-402.	2.4	53
23	Hypoxia-inducible factors as key regulators of tumor inflammation. <i>International Journal of Cancer</i> , 2013, 132, 2721-2729.	2.3	60
24	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <i>Future Oncology</i> , 2013, 9, 977-990.	1.1	21
25	Autophagy and Cancer. , 2013, , .		5
26	Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies. <i>AAPS Journal</i> , 2013, 15, 797-807.	2.2	24
27	Immunopathogenic mechanisms of systemic autoimmune disease. <i>Lancet, The</i> , 2013, 382, 819-831.	6.3	446
28	The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy. <i>Biomaterials</i> , 2013, 34, 5711-5721.	5.7	49
30	Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1161-1173.	2.0	22
31	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 1079-1090.	0.8	33
32	Dendritic-Cell-Based Therapeutic Cancer Vaccines. <i>Immunity</i> , 2013, 39, 38-48.	6.6	739
33	Current Status and Future Perspectives of Dendritic Cell-Based Cancer Immunotherapy. <i>Scandinavian Journal of Immunology</i> , 2013, 78, 167-171.	1.3	38
34	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2013, 73, 3842-3851.	0.4	86
35	Species-specific properties and translational aspects of canine dendritic cells. <i>Veterinary Immunology and Immunopathology</i> , 2013, 151, 181-192.	0.5	12
36	Exploiting dendritic cells in the development of cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1195-1210.	2.0	15
37	The Association Between Inflammation and Colorectal Cancer. , 2013, , 67-105.		2
38	Microenvironmental regulation of tumor progression and metastasis. <i>Nature Medicine</i> , 2013, 19, 1423-1437.	15.2	5,730

#	ARTICLE	IF	CITATIONS
39	CD8+ T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1769-1780.	2.0	12
40	Challenges and advances towards the rational design of mRNA vaccines. <i>Trends in Molecular Medicine</i> , 2013, 19, 705-713.	3.5	93
41	Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. <i>Cell and Tissue Banking</i> , 2013, 14, 525-560.	0.5	46
42	Dendritic Cell Vaccines. , 2013, , 273-286.		1
43	Review article: antitumoural immunity in colorectal cancer – current and potential future implications in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 3-15.	1.9	10
44	Tolerogenic Dendritic Cells: Key Regulators of Peripheral Tolerance in Health and Disease. <i>International Archives of Allergy and Immunology</i> , 2013, 161, 293-303.	0.9	26
45	Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 387-401.	1.3	17
46	Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg. <i>Blood</i> , 2013, 122, 2185-2194.	0.6	54
47	Dendritic cell immunotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 43-53.	1.1	7
48	Dendritic cell science: more than 40 years of history. <i>Journal of Leukocyte Biology</i> , 2013, 93, 33-38.	1.5	7
49	Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc (sIa) dendritic cells. <i>International Journal of Cancer</i> , 2013, 132, 1351-1359.	2.3	17
50	TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. <i>Cancer Letters</i> , 2013, 335, 119-127.	3.2	12
52	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. <i>Annals of Oncology</i> , 2013, 24, 2686-2693.	0.6	158
53	Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.	2.0	12
54	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. <i>Nature Reviews Neuroscience</i> , 2013, 14, 293-304.	4.9	106
55	Autophagy and the Tumor Microenvironment. , 2013, , 167-189.		0
56	Immunotherapy for head and neck cancer patients: shifting the balance. <i>Immunotherapy</i> , 2013, 5, 49-61.	1.0	20
57	A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. <i>BioDrugs</i> , 2013, 27, 453-468.	2.2	27

#	ARTICLE	IF	CITATIONS
58	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 729-741.	6.6	572
59	A Safe Bacterial Microsyringe for In Vivo Antigen Delivery and Immunotherapy. <i>Molecular Therapy</i> , 2013, 21, 1076-1086.	3.7	17
60	Oral administration of soluble $\beta$ -glucans extracted from <i>Grifola frondosa</i> induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. <i>International Journal of Cancer</i> , 2013, 133, 108-119.	2.3	81
61	The Tumor Immunoenvironment. , 2013, , .		4
62	Cellular immunotherapy for plasma cell myeloma. <i>Bone Marrow Transplantation</i> , 2013, 48, 1377-1386.	1.3	8
63	Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. <i>Expert Review of Vaccines</i> , 2013, 12, 285-295.	2.0	55
64	Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. <i>Immunobiology</i> , 2013, 218, 1468-1476.	0.8	30
65	Trial watch. <i>Onc Immunology</i> , 2013, 2, e23803.	2.1	92
66	Enhanced Endoplasmic Reticulum Entry of Tumor Antigen Is Crucial for Cross-Presentation Induced by Dendritic Cell-Targeted Vaccination. <i>Journal of Immunology</i> , 2013, 191, 6010-6021.	0.4	18
67	Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 34-41.	2.0	20
68	EBV and nasopharyngeal carcinoma: a target for cellular therapies. <i>Immunotherapy</i> , 2013, 5, 821-824.	1.0	6
69	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013, 12, 597-615.	2.0	60
70	Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. <i>Immunotherapy</i> , 2013, 5, 1183-1190.	1.0	2
71	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	2.0	5
73	The influence of polystyrene and poly(ether imide) inserts with different roughness, on the activation of dendritic cells. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 55, 157-168.	0.9	8
74	Twist and miR-34a Are Involved in the Generation of Tumor-Educated Myeloid-Derived Suppressor Cells. <i>International Journal of Molecular Sciences</i> , 2013, 14, 20459-20477.	1.8	13
75	Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. <i>Frontiers in Immunology</i> , 2013, 4, 496.	2.2	37
76	Antigen Choice Determines Vaccine-Induced Generation of Immunogenic versus Tolerogenic Dendritic Cells That Are Marked by Differential Expression of Pancreatic Enzymes. <i>Journal of Immunology</i> , 2013, 190, 3319-3327.	0.4	6

#	ARTICLE	IF	CITATIONS
77	Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 63.	1.3	82
78	Defective Generation and Maturation of Dendritic Cells from Monocytes in Colorectal Cancer Patients during the Course of Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 22022-22041.	1.8	41
79	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1525-1533.	3.2	58
80	Requirement of tumor-associated antigen-specific CD4 <sup>+</sup> T cells for an efficient dendritic cell vaccine in antitumor immunotherapy. <i>Immunotherapy</i> , 2013, 5, 565-567.	1.0	7
81	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 432-442.	1.3	19
82	A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 400-411.	1.2	12
83	The Duration of T Cell Stimulation Is a Critical Determinant of Cell Fate and Plasticity. <i>Science Signaling</i> , 2013, 6, ra97.	1.6	98
84	Dendritic Cell-Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2013, 36, 102-111.	1.2	25
85	A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell Responses <i>In Vivo</i> . <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	15
86	Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes. <i>Frontiers in Immunology</i> , 2013, 4, 433.	2.2	33
87	Orchestration of CD4 T Cell Epitope Preferences after Muropeptide Immunization. <i>Journal of Immunology</i> , 2013, 191, 764-772.	0.4	6
88	Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?. <i>Frontiers in Immunology</i> , 2013, 4, 454.	2.2	120
89	Regulatory Multitasking of Tolerogenic Dendritic Cells – Lessons Taken from Vitamin D3-Treated Tolerogenic Dendritic Cells. <i>Frontiers in Immunology</i> , 2013, 4, 113.	2.2	108
90	Infection and Cancer: Reevaluation of the Hygiene Hypothesis. <i>Clinical Cancer Research</i> , 2013, 19, 2834-2841.	3.2	57
91	Dendritic Cell Interactions with Lymphatic Endothelium. <i>Lymphatic Research and Biology</i> , 2013, 11, 172-182.	0.5	35
92	Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid. <i>Journal of Immunology</i> , 2013, 191, 3090-3099.	0.4	140
93	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1956-1961.	1.4	28
94	The relationship between malignant and tumor-associated cells provides a new strategy for targeted diagnosis and therapy. <i>Oncimmunology</i> , 2013, 2, e26295.	2.1	3

#	ARTICLE	IF	CITATIONS
95	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e25771.	2.1	150
96	T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment. <i>Oncolimmunology</i> , 2013, 2, e22450.	2.1	10
97	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. <i>Oncolimmunology</i> , 2013, 2, e24440.	2.1	11
98	Critical Role of AZI2 in GM-CSF-Induced Dendritic Cell Differentiation. <i>Journal of Immunology</i> , 2013, 190, 5702-5711.	0.4	22
99	Naturally circulating dendritic cells to vaccinate cancer patients. <i>Oncolimmunology</i> , 2013, 2, e23431.	2.1	27
100	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. <i>Oncolimmunology</i> , 2013, 2, e23401.	2.1	56
101	Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP. <i>Blood</i> , 2013, 122, 4230-4236.	0.6	15
102	Interleukin-15 in Gene Therapy of Cancer. <i>Current Gene Therapy</i> , 2013, 13, 15-30.	0.9	37
103	Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. <i>Oncology Reports</i> , 2013, 29, 1208-1214.	1.2	11
104	Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity. <i>Breast Cancer Research</i> , 2013, 15, R75.	2.2	53
105	Baicalin From <i>Scutellaria baicalensis</i> Impairs Th1 Polarization Through Inhibition of Dendritic Cell Maturation. <i>Journal of Pharmacological Sciences</i> , 2013, 121, 148-156.	1.1	29
106	What Are the Molecules Involved in Regulatory T-Cells Induction by Dendritic Cells in Cancer?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	22
107	Identification and Validation of Targets for Cancer Immunotherapy: From the Bench-to-Bedside. , 0, , .		0
108	Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e62847.	1.1	21
109	Using Magnetic Resonance Imaging to Evaluate Dendritic Cell-Based Vaccination. <i>PLoS ONE</i> , 2013, 8, e65318.	1.1	17
110	Depletion of CD4+ CD25+ Regulatory T Cells Promotes CCL21-Mediated Antitumor Immunity. <i>PLoS ONE</i> , 2013, 8, e73952.	1.1	24
111	Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy). <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 679-680.	0.9	8
112	VEGF in Tumor Progression and Targeted Therapy. <i>Current Cancer Drug Targets</i> , 2013, 13, 423-443.	0.8	70

#	ARTICLE	IF	CITATIONS
113	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. <i>Frontiers in Immunology</i> , 2013, 4, 417.	2.2	62
114	Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	42
115	Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	32
116	Cancer testis antigen and immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 11.	2.7	43
117	Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment. , 0, , .		0
118	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
119	Peptide-Pulsed Dendritic Cells Have Superior Ability to Induce Immune-Mediated Tissue Destruction Compared to Peptide with Adjuvant. <i>PLoS ONE</i> , 2014, 9, e92380.	1.1	12
120	Dendritic Cell-Secreted Lipocalin2 Induces CD8+ T-Cell Apoptosis, Contributes to T-Cell Priming and Leads to a TH1 Phenotype. <i>PLoS ONE</i> , 2014, 9, e101881.	1.1	30
121	Specific Activation of Dendritic Cells Enhances Clearance of Bacillus anthracis following Infection. <i>PLoS ONE</i> , 2014, 9, e109720.	1.1	2
122	Exogenous Addition of Arachidonic Acid to the Culture Media Enhances the Functionality of Dendritic Cells for Their Possible Use in Cancer Immunotherapy. <i>PLoS ONE</i> , 2014, 9, e111759.	1.1	6
123	Dendritic cell-based therapeutic cancer vaccines: past, present and future. <i>Clinical and Experimental Vaccine Research</i> , 2014, 3, 113.	1.1	65
124	Nanocarrier-based immunotherapy in cancer management and research. <i>ImmunoTargets and Therapy</i> , 2014, 3, 121.	2.7	18
125	Pathways and therapeutic targets in melanoma. <i>Oncotarget</i> , 2014, 5, 1701-1752.	0.8	202
126	Fucoidan as a Marine Anticancer Agent in Preclinical Development. <i>Marine Drugs</i> , 2014, 12, 851-870.	2.2	178
127	Colorectal cancer and immunity: What we know and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 3738.	1.4	105
128	Nanoparticles in the Development of Therapeutic Cancer Vaccines. <i>Pharmaceutical Nanotechnology</i> , 2014, 2, 2-22.	0.6	6
129	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
130	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. <i>ImmunoTargets and Therapy</i> , 2014, 3, 151.	2.7	12



#	ARTICLE	IF	CITATIONS
131	Human dendritic cell activation induced by a permannosylated dendron containing an antigenic GM <sub>3</sub> -lactone mimetic. <i>Beilstein Journal of Organic Chemistry</i> , 2014, 10, 1317-1324.	1.3	5
132	Experimental immunology Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. <i>Central-European Journal of Immunology</i> , 2014, 2, 142-151.	0.4	29
133	Tumor cell lysates as immunogenic sources for cancer vaccine design. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3261-3269.	1.4	126
134	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e28185.	2.1	36
135	slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. <i>Nature Communications</i> , 2014, 5, 3029.	5.8	36
136	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
137	Microvasculature: An essential component for organ-on-chip systems. <i>MRS Bulletin</i> , 2014, 39, 51-59.	1.7	38
138	Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors. <i>Experimental Dermatology</i> , 2014, 23, 909-915.	1.4	26
139	Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures. <i>Gene Therapy</i> , 2014, 21, 106-114.	2.3	30
140	Current advances in T-cell-based cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 1265-1278.	1.0	119
141	Human Dendritic Cells Derived From Embryonic Stem Cells Stably Modified With CD1d Efficiently Stimulate Antitumor Invariant Natural Killer T Cell Response. <i>Stem Cells Translational Medicine</i> , 2014, 3, 69-80.	1.6	6
142	Dendritic cell defects in the colorectal cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3224-3235.	1.4	72
143	Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2120-2124.	0.6	22
144	Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment. <i>Mediators of Inflammation</i> , 2014, 2014, 1-15.	1.4	100
145	Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?. <i>Frontiers in Immunology</i> , 2014, 5, 218.	2.2	12
146	Priming Dendritic Cells for Th2 Polarization: Lessons Learned from Helminths and Implications for Metabolic Disorders. <i>Frontiers in Immunology</i> , 2014, 5, 499.	2.2	56
147	Impact of the Prolymphangiogenic Crosstalk in the Tumor Microenvironment on Lymphatic Cancer Metastasis. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	22
148	From Bench to Bedside: Immunotherapy for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	18

#	ARTICLE	IF	CITATIONS
149	Stressful Presentations: Mild Cold Stress in Laboratory Mice Influences Phenotype of Dendritic Cells in Na <sup>+</sup> and Tumor-Bearing Mice. <i>Frontiers in Immunology</i> , 2014, 5, 23.	2.2	49
150	Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. <i>Frontiers in Physiology</i> , 2014, 5, 196.	1.3	28
151	Microenvironment of Tumor-Draining Lymph Nodes: Opportunities for Liposome-Based Targeted Therapy. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20209-20239.	1.8	65
152	Transforming growth factor- $\beta$ 1 deteriorates microrheological characteristics and motility of mature dendritic cells in concentration-dependent fashion. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 56, 25-40.	0.9	10
153	Cell Transfer Therapy for Cancer: Past, Present, and Future. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	0.9	30
154	Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 176.	2.2	35
155	Immunomodulatory Effects of Polysaccharide from Marine Fungus <i>Phoma herbarum</i> YS4108 on T Cells and Dendritic Cells. <i>Mediators of Inflammation</i> , 2014, 2014, 1-13.	1.4	12
156	Concurrent interaction of DCs with CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells improves secondary CTL expansion: It takes three to tango. <i>European Journal of Immunology</i> , 2014, 44, 3543-3559.	1.6	32
157	Targeting CD8 <sup>+</sup> T-cell tolerance for cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 833-852.	1.0	41
158	Dendritic cell immunotherapy in uterine cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1822-1827.	1.4	6
160	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7
161	$\beta$ T cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e27572.	2.1	158
162	Human cell-based artificial antigen-presenting cells for cancer immunotherapy. <i>Immunological Reviews</i> , 2014, 257, 191-209.	2.8	96
163	Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju329-dju329.	3.0	26
164	MAGE-A3 With Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine. <i>JAMA Surgery</i> , 2014, 149, 451.	2.2	19
165	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. , 2014, 2, 39.		16
166	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolmmunology</i> , 2014, 3, e963424.	2.1	62
167	Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. <i>MAbs</i> , 2014, 6, 108-118.	2.6	5

#	ARTICLE	IF	CITATIONS
168	Relationship of Dendritic Cell Density, HMGB1 Expression, and Tumor-infiltrating Lymphocytes in Non-Small Cell Lung Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 105-113.	0.6	21
169	Cancer Immunotherapy via Dendritic Cells. , 2014, , 75-89.		11
170	Enhanced Intracellular Targeting of Tumor-Specific Antigens. <i>JAMA Surgery</i> , 2014, 149, 457.	2.2	0
171	Therapeutic Efficacy and Systemic Antitumor T Cell Immunity Induced by RheoSwitch-Regulated IL-12 Expression after Intratumoral Injection of Adenovirus Vector or Vector-Transduced Dendritic Cells. , 2014, , 363-376.		4
172	Fucoidan Can Function as an Adjuvant In Vivo to Enhance Dendritic Cell Maturation and Function and Promote Antigen-Specific T Cell Immune Responses. <i>PLoS ONE</i> , 2014, 9, e99396.	1.1	113
173	Perspectives on Reprogramming Cancer-Associated Dendritic Cells for Anti-Tumor Therapies. <i>Frontiers in Oncology</i> , 2014, 4, 72.	1.3	16
174	Â-Catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8+ T cells. <i>Journal of Leukocyte Biology</i> , 2014, 95, 179-190.	1.5	62
175	Immune Response in Thyroid Cancer: Widening the Boundaries. <i>Scientifica</i> , 2014, 2014, 1-20.	0.6	22
176	GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	0.9	14
177	Metabolic Influences That Regulate Dendritic Cell Function in Tumors. <i>Frontiers in Immunology</i> , 2014, 5, 24.	2.2	67
178	Dendritic Cell-Targeted Vaccines. <i>Frontiers in Immunology</i> , 2014, 5, 255.	2.2	173
179	Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. <i>Frontiers in Oncology</i> , 2014, 4, 270.	1.3	3
180	Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 56-66.	2.7	4
181	IDO and CD83 expression in human epidermal Langerhans cells. <i>Journal of Dermatological Science</i> , 2014, 73, 172-174.	1.0	8
182	Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. <i>Immunobiology</i> , 2014, 219, 189-197.	0.8	7
183	PI3K in cancer-stroma interactions: bad in seed and ugly in soil. <i>Oncogene</i> , 2014, 33, 3083-3090.	2.6	55
184	The Yin and Yang of Toll-like receptors in cancer. <i>Oncogene</i> , 2014, 33, 3485-3495.	2.6	266
185	Dendritic cells regulate angiogenesis associated with liver fibrogenesis. <i>Angiogenesis</i> , 2014, 17, 119-128.	3.7	19

#	ARTICLE	IF	CITATIONS
186	Dendritic cells and cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2014, 27, 26-32.	2.4	108
187	Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 701-712.	1.2	11
188	CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful. <i>Cancer Immunology Research</i> , 2014, 2, 91-98.	1.6	276
189	Thermal ablation of tumours: biological mechanisms and advances in therapy. <i>Nature Reviews Cancer</i> , 2014, 14, 199-208.	12.8	1,477
190	Nanoparticle Adjuvant Sensing by TLR7 Enhances CD8+ T Cell-Mediated Protection from <i>Listeria Monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2014, 192, 1071-1078.	0.4	54
191	Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution. <i>Drug Discovery Today</i> , 2014, 19, 834-837.	3.2	6
192	CCR7 facilitates the pro-inflammatory function of dendritic cells in experimental leishmaniasis. <i>Parasite Immunology</i> , 2014, 36, 177-185.	0.7	3
193	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
194	Dendritic Cells in Autoimmune Disease. , 2014, , 175-186.		0
195	TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. <i>Cellular and Molecular Immunology</i> , 2014, 11, 150-159.	4.8	154
196	Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 835-845.	2.0	36
197	Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease. <i>Pathology and Oncology Research</i> , 2014, 20, 267-276.	0.9	19
198	DC-based immunotherapy for hematological malignancies. <i>International Journal of Hematology</i> , 2014, 99, 117-122.	0.7	6
199	Triggering of NF- $\kappa$ B in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy. <i>European Journal of Immunology</i> , 2014, 44, 3413-3428.	1.6	25
200	The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2151-2157.	0.8	12
201	Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity. <i>FEBS Journal</i> , 2014, 281, 3882-3893.	2.2	12
202	Wnt5a signaling increases IL-12 secretion by human dendritic cells and enhances IFN- $\gamma$ production by CD4+ T cells. <i>Immunology Letters</i> , 2014, 162, 188-199.	1.1	35
203	Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model. <i>Journal of Controlled Release</i> , 2014, 196, 161-167.	4.8	20

#	ARTICLE	IF	CITATIONS
204	Mathematical Models of Tumor-Immune System Dynamics. Springer Proceedings in Mathematics and Statistics, 2014, , .	0.1	24
205	The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. Radiation Research, 2014, 182, 219.	0.7	29
206	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
207	Targeting human dendritic cells in situ to improve vaccines. Immunology Letters, 2014, 162, 59-67.	1.1	88
208	Dendritic cell immunotherapy for glioblastoma. Expert Review of Anticancer Therapy, 2014, 14, 761-763.	1.1	5
209	Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends in Biotechnology, 2014, 32, 456-465.	4.9	182
210	Impact of myeloid cells on the efficacy of anticancer chemotherapy. Current Opinion in Immunology, 2014, 30, 24-31.	2.4	35
211	Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes. Cancer Immunology Research, 2014, 2, 436-447.	1.6	165
212	Potential of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy. Biomaterials, 2014, 35, 8186-8196.	5.7	111
213	Immunization with adenovirus LIGHT-engineered dendritic cells induces potent T cell responses and therapeutic immunity in HBV transgenic mice. Vaccine, 2014, 32, 4565-4570.	1.7	10
214	Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive. British Journal of Cancer, 2014, 111, 927-932.	2.9	31
215	High Numbers of Differentiated Effector CD4 T Cells Are Found in Patients with Cancer and Correlate with Clinical Response after Neoadjuvant Therapy of Breast Cancer. Cancer Research, 2014, 74, 2204-2216.	0.4	34
216	Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2014, 92, 153-165.	2.0	78
217	The bifacial role of helminths in cancer: Involvement of immune and non-immune mechanisms. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 138-148.	2.7	12
218	Molecular Pathways: Myeloid Complicity in Cancer. Clinical Cancer Research, 2014, 20, 5157-5170.	3.2	44
219	Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. Medical Oncology, 2014, 31, 191.	1.2	32
220	Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Journal of Translational Medicine, 2014, 12, 175.	1.8	52
221	Dendritic cell-targeted vaccines "hope or hype?". Nature Reviews Immunology, 2014, 14, 705-711.	10.6	189

#	ARTICLE	IF	CITATIONS
222	Synthesis of Multifunctional Fe <sub>3</sub> O <sub>4</sub> @CdSe/ZnS Nanoclusters Coated with Lipid A toward Dendritic Cell-Based Immunotherapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2014, 6, 5297-5307.	4.0	18
223	Bio-Hybrid Tumor Cell-Templated Capsules: A Generic Formulation Strategy for Tumor Associated Antigens in View of Immune Therapy. <i>Advanced Functional Materials</i> , 2014, 24, 7139-7150.	7.8	10
224	Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 369-380.	2.0	25
225	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 959-967.	2.0	74
226	The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34 <sup>+</sup> Hematopoietic Progenitor Cells. <i>Stem Cells and Development</i> , 2014, 23, 955-967.	1.1	53
227	The right touch: design of artificial antigen-presenting cells to stimulate the immune system. <i>Chemical Science</i> , 2014, 5, 3355.	3.7	41
228	USP18 is crucial for IFN- $\beta$ -mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity. <i>Molecular Cancer</i> , 2014, 13, 132.	7.9	31
229	Potential of Ni(II)-NTA-Modified Poly(ethylene imine) Glycopolymers as Carrier System for Future Dendritic Cell-Based Immunotherapy. <i>Biomacromolecules</i> , 2014, 15, 957-967.	2.6	14
230	Magnetic resonance and near-infrared imaging using a novel dual-modality nano-probe for dendritic cell tracking in vivo. <i>Cytotherapy</i> , 2014, 16, 699-710.	0.3	21
231	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. <i>Biomaterials</i> , 2014, 35, 5491-5504.	5.7	108
232	Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of na $\bar{v}$ e human T cells. <i>Vaccine</i> , 2014, 32, 3285-3292.	1.7	21
233	Melanoma cell lysate induces CCR7 expression and <i>in vivo</i> migration to draining lymph nodes of therapeutic human dendritic cells. <i>Immunology</i> , 2014, 142, 396-405.	2.0	20
234	Ammonia Drives Dendritic Cells into Dysfunction. <i>Journal of Immunology</i> , 2014, 193, 1080-1089.	0.4	26
235	It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes. <i>Diabetes</i> , 2014, 63, 20-30.	0.3	50
236	Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 885-899.	2.4	129
237	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 925-938.	2.0	60
238	Mechanistic explanation for platelet contribution to cancer metastasis. <i>Thrombosis Research</i> , 2014, 133, S149-S157.	0.8	134
239	Clinical use of dendritic cells for cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, e257-e267.	5.1	565

#	ARTICLE	IF	CITATIONS
240	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-poly lactide. <i>Biomaterials</i> , 2014, 35, 1686-1695.	5.7	27
241	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses. <i>Frontiers in Immunology</i> , 2014, 5, 147.	2.2	55
242	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. <i>Frontiers in Chemistry</i> , 2014, 2, 105.	1.8	147
243	Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. <i>Blood</i> , 2014, 124, 3081-3091.	0.6	167
244	Breast cancer tumor growth is efficiently inhibited by dendritic cell transfusion in a murine model. <i>Biomedical Research and Therapy</i> , 2014, 1, .	0.3	0
245	The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. <i>Cell Communication and Signaling</i> , 2015, 13, 19.	2.7	45
246	Dynamical behavior of combinational immune boost against tumor. <i>Japan Journal of Industrial and Applied Mathematics</i> , 2015, 32, 759-770.	0.5	6
247	In vitro generation of functional dendritic cells differentiated from CD34 negative cells isolated from human umbilical cord blood. <i>Cell Biology International</i> , 2015, 39, 1080-1086.	1.4	3
248	Dendritic cell developmentâ€”History, advances, and open questions. <i>Seminars in Immunology</i> , 2015, 27, 388-396.	2.7	34
249	Dendritic cell regulation of NKâ€”cell responses involves lymphotoxinâ€”1, ILâ€”12, and TGFâ€”Î²2. <i>European Journal of Immunology</i> , 2015, 45, 1783-1793.	1.6	34
250	Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. <i>Scientific Reports</i> , 2015, 5, 17695.	1.6	11
251	Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2015, 11, 3361-3367.	1.1	19
252	Effect of thymosin Î±1 on the phenotypic and functional maturation of dendritic cells from children with acute lymphoblastic leukemia. <i>Molecular Medicine Reports</i> , 2015, 12, 6093-6097.	1.1	1
253	Nonâ€”Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
255	TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. <i>Scientific Reports</i> , 2015, 5, 17622.	1.6	103
256	Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. <i>Molecular Therapy - Oncolytics</i> , 2015, 2, 15011.	2.0	42
257	Role of growth hormone in maturation and activation of dendritic cells <i>via</i> miRâ€”200a and the Keap1/Nrf2 pathway. <i>Cell Proliferation</i> , 2015, 48, 573-581.	2.4	16
258	Enhanced Humoral Responses Induced by Targeting of Antigen to Murine Dendritic Cells. <i>Scandinavian Journal of Immunology</i> , 2015, 82, 515-522.	1.3	17



#	ARTICLE	IF	CITATIONS
259	Identification of <i>Toxoplasma gondii</i> protein fractions induce immune response against melanoma in mice. <i>Apmis</i> , 2015, 123, 800-809.	0.9	4
260	Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC205 single-chain variable fragment confers adjuvanticity by triggering a TLR-mediated immune response. <i>EMBO Molecular Medicine</i> , 2015, 7, 973-988.	3.3	38
261	Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Ligand Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation. <i>Tumori</i> , 2015, 101, 637-643.	0.6	5
262	Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. <i>Small</i> , 2015, 11, 5483-5496.	5.2	103
263	Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18. <i>Journal of Immunotherapy</i> , 2015, 38, 145-154.	1.2	39
264	Myeloid Cells as Targets for Therapy in Solid Tumors. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 343-350.	1.0	32
265	Functionality of insect cell-derived colorectal cancer vaccine candidate protein pCAM <sub>5F</sub> in human dendritic cells. <i>Entomological Research</i> , 2015, 45, 162-166.	0.6	3
266	Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer. <i>International Journal of Nanomedicine</i> , 2015, 10, 1921.	3.3	16
267	Application of radiation technology in vaccines development. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 145.	1.1	52
268	Polymeric inserts differing in their chemical composition as substrates for dendritic cell cultivation. <i>Clinical Hemorheology and Microcirculation</i> , 2015, 61, 347-357.	0.9	3
269	Manipulation of Innate Immunity for Cancer Therapy in Dogs. <i>Veterinary Sciences</i> , 2015, 2, 423-439.	0.6	17
270	Biomedical insights into cell adhesion and migration from a viewpoint of central nervous system tumor immunology. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 55.	1.8	3
271	Primary Human Blood Dendritic Cells for Cancer Immunotherapy Tailoring the Immune Response by Dendritic Cell Maturation. <i>Biomedicines</i> , 2015, 3, 282-303.	1.4	22
272	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 271.	2.2	36
273	Role of Dendritic Cells in the Induction of Lymphocyte Tolerance. <i>Frontiers in Immunology</i> , 2015, 6, 535.	2.2	54
274	A subset of human plasmacytoid dendritic cells expresses CD8 $\alpha$ upon exposure to herpes simplex virus type 1. <i>Frontiers in Microbiology</i> , 2015, 6, 557.	1.5	10
275	Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. <i>Frontiers in Oncology</i> , 2015, 5, 170.	1.3	27
276	Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 176.	1.3	25



#	ARTICLE	IF	CITATIONS
277	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15006.	1.8	15
278	Enhanced anti-inflammatory potential of cinnamate-zinc layered hydroxide in lipopolysaccharide-stimulated RAW 264.7 macrophages. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2475.	2.0	15
279	Therapeutic strategy for cancer immunotherapy in head and neck cancer. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2015, 3, 27690.	0.4	5
280	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	0.9	30
281	Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect. <i>Cancer Research and Treatment</i> , 2015, 47, 518-526.	1.3	13
282	New Insights in Cutaneous Melanoma Immune-Therapy – Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
283	The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways. <i>Nature Immunology</i> , 2015, 16, 729-736.	7.0	121
284	IgE/FcγRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. <i>Cell Reports</i> , 2015, 10, 1487-1495.	2.9	61
285	A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40. <i>Journal of Hematology and Oncology</i> , 2015, 8, 35.	6.9	27
286	International society for gastrointestinal hereditary tumours – InSiGHT. <i>Familial Cancer</i> , 2015, 14, 1-91.	0.9	2
287	Dendritic Cell-Derived Exosomes may be a Tool for Cancer Immunotherapy by Converting Tumor Cells into Immunogenic Targets. <i>Frontiers in Immunology</i> , 2015, 5, 692.	2.2	112
288	Efficient delivery of antigen to DCs using yeast-derived microparticles. <i>Scientific Reports</i> , 2015, 5, 10687.	1.6	31
289	Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines. <i>Scientific Reports</i> , 2015, 5, 10276.	1.6	88
290	Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. <i>Stem Cell Research and Therapy</i> , 2015, 6, 184.	2.4	35
291	The immunological effect of hyaluronan in tumor angiogenesis. <i>Clinical and Translational Immunology</i> , 2015, 4, e52.	1.7	46
292	Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. <i>International Journal of Oncology</i> , 2015, 46, 1699-1709.	1.4	40
293	Low Noncytotoxic Concentrations of 5-Fluorouracil Have No Adverse Effects on Maturation and Function of Bone Marrow-Derived Dendritic Cells in vitro: A Potentially Safe Adjuvant for Dendritic Cell-Based Cancer Therapy. <i>International Archives of Allergy and Immunology</i> , 2015, 168, 122-130.	0.9	3
294	Dendritic cell-based vaccine research against cancer. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 213-232.	1.3	28

#	ARTICLE	IF	CITATIONS
295	HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 5-15.	1.1	67
296	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmunology</i> , 2015, 4, e974411.	2.1	97
297	Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor $\beta$ . <i>Cancer Research</i> , 2015, 75, 1265-1274.	0.4	26
298	Emerging Functions of Amphiregulin in Orchestrating Immunity, Inflammation, and Tissue Repair. <i>Immunity</i> , 2015, 42, 216-226.	6.6	429
299	DC3-Decorated Polyplexes for Targeted Gene Delivery into Dendritic Cells. <i>Bioconjugate Chemistry</i> , 2015, 26, 213-224.	1.8	11
300	Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. <i>British Journal of Neurosurgery</i> , 2015, 29, 197-205.	0.4	21
301	Infection and immunity on a chip: a compartmentalised microfluidic platform to monitor immune cell behaviour in real time. <i>Lab on A Chip</i> , 2015, 15, 1481-1487.	3.1	38
302	<i>Mycobacterium indicus pranii</i> induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner. <i>Journal of Leukocyte Biology</i> , 2015, 97, 511-520.	1.5	19
303	Immunotherapy of melanoma: Present options and future promises. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 115-128.	2.7	59
304	Dendritic-cell-based technology landscape: Insights from patents and citation networks. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 682-688.	1.4	9
305	Immune Response Regulation in the Tumor Microenvironment by Hypoxia. <i>Seminars in Oncology</i> , 2015, 42, 378-386.	0.8	121
306	$\beta$ -Catenin Promotes Regulatory T-cell Responses in Tumors by Inducing Vitamin A Metabolism in Dendritic Cells. <i>Cancer Research</i> , 2015, 75, 656-665.	0.4	94
307	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	13.7	429
308	Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. <i>Cancer Science</i> , 2015, 106, 397-406.	1.7	65
309	A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy. <i>Journal of Theoretical Biology</i> , 2015, 380, 569-584.	0.8	24
310	Efficacy of intravesical <i>Bacillus Calmette-Guérin</i> therapy against tumor immune escape in an orthotopic model of bladder cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 162-166.	0.8	8
311	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 125-140.	1.0	27
313	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2015, 4, e1008814.	2.1	102

#	ARTICLE	IF	CITATIONS
314	Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1063-1067.	0.8	33
315	Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. <i>Oncology Letters</i> , 2015, 9, 1549-1556.	0.8	18
316	pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon- $\beta$ gene lipoplex for efficient cancer immunotherapy. <i>Biomaterials</i> , 2015, 67, 214-224.	5.7	83
317	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
318	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41
319	Transcutaneous immunization against cancer using solid-in-oil nanodispersions. <i>MedChemComm</i> , 2015, 6, 1387-1392.	3.5	16
320	Targeting cancer with kinase inhibitors. <i>Journal of Clinical Investigation</i> , 2015, 125, 1780-1789.	3.9	364
321	Radiation-driven lipid accumulation and dendritic cell dysfunction in cancer. <i>Scientific Reports</i> , 2015, 5, 9613.	1.6	60
322	Cancer vaccines. <i>BMJ</i> , The, 2015, 350, h988-h988.	3.0	199
323	Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer. <i>Biomaterials</i> , 2015, 54, 177-187.	5.7	52
324	$\beta$ -Glucan enhances cytotoxic T lymphocyte responses by activation of human monocyte-derived dendritic cells via the PI3K/AKT pathway. <i>Human Immunology</i> , 2015, 76, 146-154.	1.2	30
325	Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. <i>Oncotmmunology</i> , 2015, 4, e1008355.	2.1	78
326	Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 650-656.	1.4	41
327	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 381-388.	2.0	70
328	Engineering monocyte-derived dendritic cells to secrete interferon- $\alpha$ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	2.0	27
330	Fever and the thermal regulation of immunity: the immune system feels the heat. <i>Nature Reviews Immunology</i> , 2015, 15, 335-349.	10.6	795
331	ALA-PDT mediated DC vaccine for skin squamous cell carcinoma. , 2015, , .		0
332	Umbilical cord blood-derived cellular products for cancer immunotherapy. <i>Cytotherapy</i> , 2015, 17, 739-748.	0.3	22

#	ARTICLE	IF	CITATIONS
333	PAMAM Dendron Lipid Assemblies That Undergo Structural Transition in Response to Weakly Acidic pH and Their Cytoplasmic Delivery Capability. <i>Langmuir</i> , 2015, 31, 5105-5114.	1.6	16
334	Synthetic immunity to break down the bottleneck of cancer immunotherapy. <i>Science Bulletin</i> , 2015, 60, 977-985.	4.3	4
335	<sup>89</sup> Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies. <i>Radiology</i> , 2015, 275, 490-500.	3.6	121
336	Antigen-loaded Dendritic Cell Migration: MR Imaging in a Pancreatic Carcinoma Model. <i>Radiology</i> , 2015, 274, 192-200.	3.6	26
337	Engineering Nanoparticle-Coated Bacteria as Oral DNA Vaccines for Cancer Immunotherapy. <i>Nano Letters</i> , 2015, 15, 2732-2739.	4.5	213
338	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2015, 35, S185-S198.	4.3	1,122
339	Photodynamic Therapy-mediated Cancer Vaccination Enhances Stem-like Phenotype and Immune Escape, Which Can Be Blocked by Thrombospondin-1 Signaling through CD47 Receptor Protein. <i>Journal of Biological Chemistry</i> , 2015, 290, 8975-8986.	1.6	17
340	Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. <i>OncImmunology</i> , 2015, 4, e1016699.	2.1	8
341	Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1071-1078.	0.6	135
342	Soluble $\beta$ -glucan from <i>Grifola frondosa</i> induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity. <i>Journal of Leukocyte Biology</i> , 2015, 98, 1015-1025.	1.5	22
343	Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. <i>Journal of Immunology</i> , 2015, 195, 4537-4544.	0.4	12
344	CD8 + T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. <i>BMC Systems Biology</i> , 2015, 9, 27.	3.0	16
345	Dendritic Cell Immune Therapy to Break or Induce Tolerance. <i>Current Stem Cell Reports</i> , 2015, 1, 197-205.	0.7	5
346	Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca <sup>2+</sup> transport ATPase 2 regulation. <i>Cytotherapy</i> , 2015, 17, 1421-1433.	0.3	15
347	Cancer immunotherapy via nucleic acid aptamers. <i>International Immunopharmacology</i> , 2015, 29, 926-936.	1.7	44
348	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1491-1500.	1.4	6
349	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2015, 67, 731-753.	7.1	129
350	Injectable cryogel-based whole-cell cancer vaccines. <i>Nature Communications</i> , 2015, 6, 7556.	5.8	312

#	ARTICLE	IF	CITATIONS
351	Grundlagen der gastrointestinalen Tumorerkrankungen. , 2015, , 397-459.		0
352	Nanoparticulate immunotherapy for cancer. <i>Journal of Controlled Release</i> , 2015, 219, 167-180.	4.8	80
353	Self-Assembled DNA Immunonanostructures as Multivalent CpG Nanoagents. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 24069-24074.	4.0	101
354	Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. <i>Onc Immunology</i> , 2015, 4, e1008342.	2.1	19
355	Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant. <i>Journal of Virology</i> , 2015, 89, 10612-10624.	1.5	61
356	In vitro antitumor immune response induced by dendritic cells transduced with human $\text{I}\kappa\text{B}\beta$ recombinant adenovirus. <i>Cellular Immunology</i> , 2015, 297, 46-52.	1.4	5
357	Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies—A review. <i>Onc Immunology</i> , 2015, 4, e1002720.	2.1	31
358	Trial Watch: Adoptive cell transfer for oncological indications. <i>Onc Immunology</i> , 2015, 4, e1046673.	2.1	29
359	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Onc Immunology</i> , 2015, 4, e1026531.	2.1	26
361	Low CD1c <sup>+</sup> myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection. <i>BMC Infectious Diseases</i> , 2015, 15, 342.	1.3	2
362	CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. <i>Biomaterials</i> , 2015, 40, 88-97.	5.7	235
363	Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. <i>Cancer Research</i> , 2015, 75, 5-10.	0.4	261
364	Chitoooligosaccharides from the shrimp chitosan hydrolysate induces differentiation of murine RAW264.7 macrophages into dendritic-like cells. <i>Journal of Functional Foods</i> , 2015, 12, 70-79.	1.6	13
365	Synthetic immunology: modulating the human immune system. <i>Trends in Biotechnology</i> , 2015, 33, 65-79.	4.9	41
366	Immune Effects of Bevacizumab: Killing Two Birds with One Stone. <i>Cancer Microenvironment</i> , 2015, 8, 15-21.	3.1	49
367	Concise Review: Engineering the Fusion of Cytokines for the Modulation of Immune Cellular Responses in Cancer and Autoimmune Disorders. <i>Stem Cells Translational Medicine</i> , 2015, 4, 66-73.	1.6	18
368	Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 79-94.	1.4	20
369	mRNA-based dendritic cell vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 161-176.	2.0	121

#	ARTICLE	IF	CITATIONS
370	High-risk corneal allografts: A therapeutic challenge. <i>World Journal of Transplantation</i> , 2016, 6, 10.	0.6	32
371	Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. <i>Oncotarget</i> , 2016, 7, 77825-77837.	0.8	64
372	Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. <i>Journal of Clinical Trials</i> , 2016, 06, .	0.1	23
373	A Multi-Compartment Hybrid Computational Model Predicts Key Roles for Dendritic Cells in Tuberculosis Infection. <i>Computation</i> , 2016, 4, 39.	1.0	39
374	Differential Effects of <i>Viscum album</i> Preparations on the Maturation and Activation of Human Dendritic Cells and CD4+ T Cell Responses. <i>Molecules</i> , 2016, 21, 912.	1.7	15
375	Improving the clinical impact of biomaterials in cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 15421-15443.	0.8	56
376	The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model. <i>Medical Science Monitor</i> , 2016, 22, 1309-1317.	0.5	15
377	Maturation of dendritic cells by pullulan promotes anti-cancer effect. <i>Oncotarget</i> , 2016, 7, 44644-44659.	0.8	23
378	A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 40437-40450.	0.8	50
379	Hallmarks of glioblastoma: a systematic review. <i>ESMO Open</i> , 2016, 1, e000144.	2.0	122
380	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	153
381	Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. <i>Case Reports in Medicine</i> , 2016, 2016, 1-7.	0.3	20
382	Development of Novel Immunotherapies for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1506.	1.8	22
383	Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. <i>Vaccines</i> , 2016, 4, 8.	2.1	68
384	Harnessing the immune system to improve cancer therapy. <i>Annals of Translational Medicine</i> , 2016, 4, 261-261.	0.7	225
385	Modulation of Inflammatory Responses by Wnt/ $\beta$ -Catenin Signaling in Dendritic Cells: A Novel Immunotherapy Target for Autoimmunity and Cancer. <i>Frontiers in Immunology</i> , 2016, 7, 460.	2.2	102
386	Context-Specific and Immune Cell-Dependent Antitumor Activities of $\beta$ -1-Antitrypsin. <i>Frontiers in Immunology</i> , 2016, 7, 559.	2.2	16
387	The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 643.	1.8	97

#	ARTICLE	IF	CITATIONS
388	Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. PLoS ONE, 2016, 11, e0146622.	1.1	27
389	Epithelium Expressing the E7 Oncoprotein of HPV16 Attracts Immune-Modulatory Dendritic Cells to the Skin and Suppresses Their Antigen-Processing Capacity. PLoS ONE, 2016, 11, e0152886.	1.1	24
390	Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination. Immune Network, 2016, 16, 33.	1.6	50
391	Current Approaches of Photothermal Therapy in Treating Cancer Metastasis with Nanotherapeutics. Theranostics, 2016, 6, 762-772.	4.6	724
392	Regulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation. Immunological Reviews, 2016, 272, 28-38.	2.8	20
393	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	1.2	26
394	Mucosal expression of DEC-205 targeted allergen alleviates an asthmatic phenotype in mice. Journal of Controlled Release, 2016, 237, 14-22.	4.8	12
395	Stem Cell Membrane-Coated Nanogels for Highly Efficient In Vivo Tumor Targeted Drug Delivery. Small, 2016, 12, 4056-4062.	5.2	271
396	Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunological Reviews, 2016, 271, 260-275.	2.8	277
397	Dendritic cell chimerism in oral mucosa of transplanted patients affected by graft-versus-host disease. Journal of Oral Pathology and Medicine, 2016, 45, 127-135.	1.4	2
398	Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma. Journal of Neuro-Oncology, 2016, 129, 289-300.	1.4	8
399	Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy. Advanced Healthcare Materials, 2016, 5, 1413-1419.	3.9	48
400	In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scientific Reports, 2016, 6, 38348.	1.6	55
401	Ultrastructural demonstration of antigen presenting cells in appendix. Journal of the Anatomical Society of India, 2016, 65, 61-64.	0.1	1
402	Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3-Dioxygenase Mediated-antitumor Efficiency. Molecular Therapy - Nucleic Acids, 2016, 5, e397.	2.3	7
403	The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nature Communications, 2016, 7, 13720.	5.8	217
404	Dendritic cell vaccines for melanoma: past, present and future. Melanoma Management, 2016, 3, 273-289.	0.1	20
405	The use of dendritic cell vaccinations in melanoma: where are we now?. Melanoma Management, 2016, 3, 247-250.	0.1	3



#	ARTICLE	IF	CITATIONS
406	Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. <i>Journal of Immunotherapy</i> , 2016, 39, 249-259.	1.2	8
407	Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. <i>BMJ Open</i> , 2016, 6, e013904.	0.8	63
408	A non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells. <i>BMC Neuroscience</i> , 2016, 17, 30.	0.8	45
409	Dendritic Cells in the Immune System—History, Lineages, Tissues, Tolerance, and Immunity. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	28
410	Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles. <i>Journal of Drug Targeting</i> , 2016, 24, 780-786.	2.1	28
411	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	1.0	34
412	Immune Monitoring Using mRNA-Transfected Dendritic Cells. <i>Methods in Molecular Biology</i> , 2016, 1428, 245-259.	0.4	3
414	Nanomedicine. <i>Advances in Delivery Science and Technology</i> , 2016, , .	0.4	6
415	Investigational new drugs for brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 937-956.	1.9	16
416	Dendritic Cell—Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	3.2	295
417	DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1072674.	2.1	25
418	Understanding dendritic cell immunotherapy in ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 643-652.	1.1	6
419	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. <i>International Journal of Oncology</i> , 2016, 48, 953-964.	1.4	33
420	Omics Profiling in Precision Oncology. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2525-2536.	2.5	84
421	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016, 15, 1327-1336.	2.0	79
422	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
423	TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models. <i>Oncolmmunology</i> , 2016, 5, e1178420.	2.1	10
424	Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. <i>Blood</i> , 2016, 127, 722-734.	0.6	39



#	ARTICLE	IF	CITATIONS
425	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. <i>Oncolmmunology</i> , 2016, 5, e1227902.	2.1	26
426	Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 127-161.	0.1	0
427	Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2016, 64, 167-174.	1.3	41
428	Immune Complexes Mimicking Synthetic Vaccine Nanoparticles for Enhanced Migration and Cross-Presentation of Dendritic Cells. <i>Advanced Functional Materials</i> , 2016, 26, 8072-8082.	7.8	39
429	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. <i>Medical Oncology</i> , 2016, 33, 63.	1.2	15
430	Changes in expression of genes involved in antitumor immunity in mice vaccinated with tumor vaccine composed of irradiated syngeneic tumor cells and CpG oligodeoxynucleotides. <i>Molecular Immunology</i> , 2016, 79, 1-13.	1.0	2
431	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1090-1105.	7.7	217
432	Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticulate cancer therapy. <i>Nanomedicine</i> , 2016, 11, 2735-2751.	1.7	18
433	Covalent Conjugation of Small-Molecule Adjuvants to Nanoparticles Induces Robust Cytotoxic T Cell Responses via DC Activation. <i>Bioconjugate Chemistry</i> , 2016, 27, 2007-2013.	1.8	28
434	Curdlan activates dendritic cells through dectin-1 and toll-like receptor 4 signaling. <i>International Immunopharmacology</i> , 2016, 39, 71-78.	1.7	53
435	Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. <i>Journal of the American Chemical Society</i> , 2016, 138, 12502-12510.	6.6	429
436	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	2
437	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 2715-2725.	0.4	43
438	Solid lipid nanodispersions for transdermal drug delivery systems. <i>Biotechnology Journal</i> , 2016, 11, 1375-1385.	1.8	38
439	Precision glycoalyx editing as a strategy for cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10304-10309.	3.3	328
440	Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene. <i>Gene Therapy</i> , 2016, 23, 839-845.	2.3	2
441	The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. <i>British Journal of Pharmacology</i> , 2016, 173, 3041-3079.	2.7	71
442	Autophagy Networks in Inflammation. , 2016, , .		3

#	ARTICLE	IF	CITATIONS
443	Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype. <i>Scientific Reports</i> , 2016, 6, 29712.	1.6	10
444	Toll-like receptors targeting technology for the treatment of lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1047-1059.	2.5	5
445	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmunology</i> , 2016, 5, e1214790.	2.1	64
446	Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor. <i>Cancer Medicine</i> , 2016, 5, 325-336.	1.3	22
447	Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. <i>Biomaterials</i> , 2016, 104, 310-322.	5.7	114
448	Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. <i>Immunology Letters</i> , 2016, 177, 25-37.	1.1	8
449	M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T cell proliferation. <i>Immunology</i> , 2016, 149, 320-328.	2.0	78
450	Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. <i>Transfusion and Apheresis Science</i> , 2016, 55, 146-152.	0.5	11
452	Immunotherapy for oesophagogastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1197-1207.	1.4	10
453	Foldable glycoprobes capable of fluorogenic crosslinking of biomacromolecules. <i>Chemical Science</i> , 2016, 7, 6325-6329.	3.7	32
454	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3204-3212.	0.8	46
455	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6731-E6740.	3.3	95
456	One microenvironment does not fit all: heterogeneity beyond cancer cells. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 601-629.	2.7	58
457	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016, 8, 334ps9.	5.8	162
458	microRNA-155 deficiency impairs dendritic cell function in breast cancer. <i>Oncolmunology</i> , 2016, 5, e1232223.	2.1	39
459	Inhibition of Notch 1 receptor influenced the differentiation of Lin-CD45RA-dendritic cell precursors within ovarian carcinoma microenvironment. <i>BMC Immunology</i> , 2016, 17, 14.	0.9	3
460	Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. <i>Scientific Reports</i> , 2016, 6, 19049.	1.6	179
461	Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13193.	5.8	1,270

#	ARTICLE	IF	CITATIONS
462	Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma. <i>Experimental Cell Research</i> , 2016, 349, 264-272.	1.2	14
463	<i>Viral and Nonviral Cancer Gene Therapy</i> . , 2016, , 1-52.		1
464	Mathematical modeling and analysis of combinational immune boost for tumor elimination. <i>AIP Conference Proceedings</i> , 2016, , .	0.3	4
465	Adoptive immunotherapy via CD4+ versus CD8+ T cells. <i>Biomedical Research and Therapy</i> , 2016, 3, .	0.3	1
466	Equine dendritic cells generated with horse serum have enhanced functionality in comparison to dendritic cells generated with fetal bovine serum. <i>BMC Veterinary Research</i> , 2016, 12, 254.	0.7	12
467	Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function. <i>Cytotechnology</i> , 2016, 68, 2223-2233.	0.7	13
468	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732.	2.1	17
469	CMRF-56 <sup>+</sup> blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncolmmunology</i> , 2016, 5, e1168555.	2.1	17
470	Mathematical model of tumor immune surveillance. <i>Journal of Theoretical Biology</i> , 2016, 404, 312-330.	0.8	63
472	Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence. <i>NPG Asia Materials</i> , 2016, 8, e281-e281.	3.8	51
473	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	1.4	15
474	The role of myeloid cells in cancer therapies. <i>Nature Reviews Cancer</i> , 2016, 16, 447-462.	12.8	570
475	A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. <i>Oncolmmunology</i> , 2016, 5, e1151592.	2.1	17
476	Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. <i>Immunobiology</i> , 2016, 221, 166-174.	0.8	5
477	Cancer vaccine triggers antiviral-type defences. <i>Nature</i> , 2016, 534, 329-331.	13.7	27
478	Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1113-1123.	1.4	9
479	C-type lectin receptors in the control of T helper cell differentiation. <i>Nature Reviews Immunology</i> , 2016, 16, 433-448.	10.6	200
480	Recent advances in the development of nanomaterials for DC-based immunotherapy. <i>Science Bulletin</i> , 2016, 61, 514-523.	4.3	9

#	ARTICLE	IF	CITATIONS
481	Polymer-Based DNA Delivery Systems for Cancer Immunotherapy. <i>Advances in Delivery Science and Technology</i> , 2016, , 221-244.	0.4	1
482	Phenotypic and functional comparison of two distinct subsets of programmable cell of monocytic origin (PCMOs)-derived dendritic cells with conventional monocyte-derived dendritic cells. <i>Cellular and Molecular Immunology</i> , 2016, 13, 160-169.	4.8	6
483	Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2016, 13, 1077-1082.	1.1	8
484	IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 193-204.	2.0	83
485	Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. <i>Thrombosis Research</i> , 2016, 139, 65-76.	0.8	162
486	Adeno-associated virus (AAV) vectors in cancer gene therapy. <i>Journal of Controlled Release</i> , 2016, 240, 287-301.	4.8	137
487	Trial Watchâ€”Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52
488	Single-cell analysis tools for drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 204-216.	21.5	407
489	Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 139, 10-16.	2.5	31
490	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldenceI-T). <i>Future Oncology</i> , 2016, 12, 751-762.	1.1	18
491	Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. <i>Nanomedicine</i> , 2016, 11, 479-494.	1.7	36
492	Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. <i>Biomaterials</i> , 2016, 90, 72-84.	5.7	76
493	Dendritic Cells in the Context of Human Tumors: Biology and Experimental Tools. <i>International Reviews of Immunology</i> , 2016, 35, 116-135.	1.5	14
494	A Threeâ€Component Assembly Promoted by Boronic Acids Delivers a Modular Fluorophore Platform (BASHY Dyes). <i>Chemistry - A European Journal</i> , 2016, 22, 1631-1637.	1.7	56
495	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
496	Generation of mouse and human dendritic cells in vitro. <i>Journal of Immunological Methods</i> , 2016, 432, 24-29.	0.6	34
497	Methods for measuring myeloperoxidase activity toward assessing inhibitor efficacy in living systems. <i>Journal of Leukocyte Biology</i> , 2016, 99, 541-548.	1.5	47
498	RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?. <i>Materials Today</i> , 2016, 19, 29-43.	8.3	31

#	ARTICLE	IF	CITATIONS
499	DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1117-1123.	1.4	0
500	DNA-organic hybrid nanovaccine for cancer immunotherapy. <i>Nanoscale</i> , 2016, 8, 6684-6692.	2.8	54
501	Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1418-1429.	1.4	70
502	A Generic Polymer-Protein Ligation Strategy for Vaccine Delivery. <i>Biomacromolecules</i> , 2016, 17, 874-881.	2.6	11
503	Hydrophobic chain modified low molecular weight polyethylenimine for efficient antigen delivery. <i>RSC Advances</i> , 2016, 6, 13636-13643.	1.7	9
504	Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice. <i>Immunobiology</i> , 2016, 221, 813-821.	0.8	12
505	Immunotherapy of Cancer. , 2016, , .		3
506	Dendritic Cell-Based Vaccine for Cancer. , 2016, , 197-220.		0
507	NKT Cell-Based Immunotherapy. , 2016, , 75-86.		0
508	Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. <i>Onc Immunology</i> , 2016, 5, e1057385.	2.1	31
509	Molecular mechanisms for enhanced DNA vaccine immunogenicity. <i>Expert Review of Vaccines</i> , 2016, 15, 313-329.	2.0	231
510	Self-adjuvanted hyaluronate antigenic peptide conjugate for transdermal treatment of muscular dystrophy. <i>Biomaterials</i> , 2016, 81, 93-103.	5.7	21
511	Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells. <i>Cellular Immunology</i> , 2016, 300, 46-53.	1.4	33
512	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. <i>Annals of Oncology</i> , 2016, 27, 409-416.	0.6	597
513	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
514	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
515	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	3.2	211
516	Spontaneous Protein Adsorption on Graphene Oxide Nanosheets Allowing Efficient Intracellular Vaccine Protein Delivery. <i>ACS Applied Materials &amp; Interfaces</i> , 2016, 8, 1147-1155.	4.0	99

#	ARTICLE	IF	CITATIONS
517	Deletion of LRP5 and LRP6 in dendritic cells enhances antitumor immunity. <i>Oncolmmunology</i> , 2016, 5, e1115941.	2.1	72
518	Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies. <i>Cancer Discovery</i> , 2016, 6, 17-19.	7.7	8
519	Dendritic cells in brain diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 352-367.	1.8	51
520	Dendritic cell targeted vaccines: Recent progresses and challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 612-622.	1.4	62
521	Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives. <i>Bone Marrow Transplantation</i> , 2016, 51, 163-171.	1.3	26
522	Nanotechnology for protein delivery: Overview and perspectives. <i>Journal of Controlled Release</i> , 2016, 240, 24-37.	4.8	294
523	The thyroid hormone triiodothyronine reinvigorates dendritic cells and potentiates anti-tumor immunity. <i>Oncolmmunology</i> , 2016, 5, e1064579.	2.1	14
524	Personalized approaches to active immunotherapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 72-82.	3.3	41
525	Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice. <i>Cellular and Molecular Immunology</i> , 2016, 13, 850-861.	4.8	27
526	Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity. <i>Oncolmmunology</i> , 2017, 6, e1282589.	2.1	27
527	Succinate in the cancerâ€œimmune cycle. <i>Cancer Letters</i> , 2017, 390, 45-47.	3.2	74
528	Activation of dendritic cells by low molecular weight oyster polysaccharides. <i>International Immunopharmacology</i> , 2017, 44, 183-190.	1.7	7
529	A current perspective on cancer immune therapy: stepâ€œbyâ€œstep approach to constructing the magic bullet. <i>Clinical and Translational Medicine</i> , 2017, 6, 3.	1.7	58
530	TGF-Î², Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022285.	2.3	47
531	Cell Based Therapy: Modified Cancer Cells. , 2017, , 23-46.		0
532	Plant-Made Vaccines in the Fight Against Cancer. <i>Trends in Biotechnology</i> , 2017, 35, 241-256.	4.9	20
533	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
534	Combating Established Mouse Glioblastoma through Nicotinylatedâ€œLiposomesâ€œMediated Targeted Chemotherapy in Combination with Dendriticâ€œCellâ€œBased Genetic Immunization. <i>Advanced Biology</i> , 2017, 1, e1600009.	3.0	15

#	ARTICLE	IF	CITATIONS
535	Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3352-3364.	3.2	24
536	Initiative action of tumor-associated macrophage during tumor metastasis. <i>Biochimie Open</i> , 2017, 4, 8-18.	3.2	63
537	Enhanced Spacer Length between Mannose Mimicking Shikimoyl and Quinoyl Headgroups and Hydrophobic Region of Cationic Amphiphile Increases Efficiency of Dendritic Cell Based DNA Vaccination: A Structure-Activity Investigation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1605-1610.	2.9	14
538	Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. <i>Translational Oncology</i> , 2017, 10, 132-141.	1.7	12
539	Next-generation dendritic cell-based vaccines for leukemia patients. <i>Immunotherapy</i> , 2017, 9, 173-181.	1.0	9
540	Rationale for stimulator of interferon genes-targeted cancer immunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 86-97.	1.3	47
541	Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model. <i>Oncology Reports</i> , 2017, 37, 171-178.	1.2	22
542	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4416-4428.	3.2	252
543	Nanomedicine approaches to improve cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1456.	3.3	39
544	Potential of immunotherapy for sarcoma. <i>Cancer</i> , 2017, 123, 1488-1489.	2.0	4
545	Immune modulation by dendritic-cell-based cancer vaccines. <i>Journal of Biosciences</i> , 2017, 42, 161-173.	0.5	15
546	Dendritic Cells Targeting and pH-Responsive Multi-layered Nanocomplexes for Smart Delivery of DNA Vaccines. <i>AAPS PharmSciTech</i> , 2017, 18, 2618-2625.	1.5	10
547	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. <i>Nucleus (India)</i> , 2017, 60, 93-109.	0.9	4
548	Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. <i>Acta Biomaterialia</i> , 2017, 53, 367-377.	4.1	34
549	Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses <i>in vivo</i> . <i>Oncolmmunology</i> , 2017, 6, e1285991.	2.1	20
550	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	178
551	The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. <i>Seminars in Cancer Biology</i> , 2017, 45, 23-35.	4.3	32
552	Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82.	6.9	105



#	ARTICLE	IF	CITATIONS
553	Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	422
554	Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2017, 256, 170-181.	4.8	128
555	Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1713-1732.	1.2	12
556	Dendritic cell based vaccination strategy: an evolving paradigm. <i>Journal of Neuro-Oncology</i> , 2017, 133, 223-235.	1.4	39
557	Monocyte-derived dendritic cells from patients with cervical intraepithelial lesions. <i>Oncology Letters</i> , 2017, 13, 1456-1462.	0.8	10
558	Cutaneous Dendritic Cells in Health and Disease. , 2017, , 137-150.		0
559	Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy. <i>Frontiers of Chemical Science and Engineering</i> , 2017, 11, 676-684.	2.3	9
560	Trial watch: Dendritic cell-based anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1328341.	2.1	87
561	Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. <i>Journal of Controlled Release</i> , 2017, 258, 182-195.	4.8	79
562	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. <i>Journal of Translational Medicine</i> , 2017, 15, 104.	1.8	100
563	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR $\alpha$ B1. <i>European Journal of Immunology</i> , 2017, 47, 1108-1118.	1.6	23
564	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017, 9, 507-520.	1.0	12
565	A Freeze-Concentration and Polyampholyte-Modified Liposome-Based Antigen-Delivery System for Effective Immunotherapy. <i>Advanced Healthcare Materials</i> , 2017, 6, 1700207.	3.9	9
566	The inflammatory cytokine IL-22 promotes murine gliomas via proliferation. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1087-1092.	0.8	7
567	Polyelectrolyte-Enrobed Cancer Cells in View of Personalized Immune-Therapy. <i>Advanced Science</i> , 2017, 4, 1700050.	5.6	18
568	Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. <i>Annual Review of Immunology</i> , 2017, 35, 229-253.	9.5	96
569	Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma. <i>Brain, Behavior, and Immunity</i> , 2017, 65, 140-149.	2.0	46
570	Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. <i>Chemical Society Reviews</i> , 2017, 46, 3830-3852.	18.7	719



#	ARTICLE	IF	CITATIONS
571	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. <i>Cancer Biology and Therapy</i> , 2017, 18, 451-469.	1.5	35
572	Dendritic Cells. , 2017, , 171-181.		0
573	Facilitating the presentation of antigen peptides on dendritic cells for cancer immunotherapy using a polymer-based synthetic receptor. <i>MedChemComm</i> , 2017, 8, 1207-1212.	3.5	1
574	Autophagy in natural and therapy-driven anticancer immunosurveillance. <i>Autophagy</i> , 2017, 13, 2163-2170.	4.3	52
575	Anti-inflammatory potential of hentriacontane in LPS stimulated RAW 264.7 cells and mice model. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 175-186.	2.5	39
576	Herpes Simplex Virus Glycoprotein D Targets a Specific Dendritic Cell Subset and Improves the Performance of Vaccines to Human Papillomavirus-Associated Tumors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1922-1933.	1.9	15
577	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. <i>Advanced Materials</i> , 2017, 29, 1606036.	11.1	220
578	Avidin-conjugated calcium phosphate nanoparticles as a modular targeting system for the attachment of biotinylated molecules in vitro and in vivo. <i>Acta Biomaterialia</i> , 2017, 57, 414-425.	4.1	23
579	Personalized peptide vaccines and their relation to other therapies in urological cancer. <i>Nature Reviews Urology</i> , 2017, 14, 501-510.	1.9	30
580	Nanomaterial-based cancer immunotherapy. <i>Journal of Materials Chemistry B</i> , 2017, 5, 5517-5531.	2.9	34
581	Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses. <i>Advances in Cell Biology</i> , 2017, 5, 72-95.	1.5	0
582	Display of DNA on Nanoparticles for Targeting Antigen Presenting Cells. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 496-501.	2.6	32
583	Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. <i>Tumor Biology</i> , 2017, 39, 101042831769502.	0.8	52
584	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. <i>Journal of Neuro-Oncology</i> , 2017, 134, 541-549.	1.4	109
585	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
586	Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. <i>ACS Nano</i> , 2017, 11, 4463-4474.	7.3	583
587	The Microenvironmental Landscape of Brain Tumors. <i>Cancer Cell</i> , 2017, 31, 326-341.	7.7	1,163
588	A Light Responsive Nanoparticle-Based Delivery System Using Pheophorbide A Graft Polyethylenimine for Dendritic Cell-Based Cancer Immunotherapy. <i>Molecular Pharmaceutics</i> , 2017, 14, 1760-1770.	2.3	64

#	ARTICLE	IF	CITATIONS
589	Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life. <i>Immunity</i> , 2017, 46, 504-515.	6.6	230
590	Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. <i>International Review of Cell and Molecular Biology</i> , 2017, 330, 115-156.	1.6	22
591	Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. <i>Onc Immunology</i> , 2017, 6, e1265717.	2.1	25
592	B cell antigen extraction is regulated by physical properties of antigen-presenting cells. <i>Journal of Cell Biology</i> , 2017, 216, 217-230.	2.3	129
593	Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways. <i>Biochemistry and Cell Biology</i> , 2017, 95, 99-109.	0.9	68
594	Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2961-2971.	3.2	105
595	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
596	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392
598	Effects of engineered nanoparticles on the innate immune system. <i>Seminars in Immunology</i> , 2017, 34, 25-32.	2.7	189
599	Nanomaterial-Enabled Immunotherapeutic Applications. , 2017, , 319-329.		0
600	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
601	Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA. <i>Tumor Biology</i> , 2017, 39, 101042831773336.	0.8	21
602	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 360-373.	1.5	10
603	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
604	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii44-xii55.	0.6	170
605	Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells. <i>Nature Communications</i> , 2017, 8, 1109.	5.8	111
606	Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. <i>Scientific Reports</i> , 2017, 7, 13902.	1.6	15
607	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. <i>Onc Immunology</i> , 2017, 6, e1362528.	2.1	15

#	ARTICLE	IF	CITATIONS
608	Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. <i>Cancer Science</i> , 2017, 108, 1947-1952.	1.7	189
609	Capturing "Extraordinary" Soft-Assembled Charge-Like Polypeptides as a Strategy for Nanocarrier Design. <i>Advanced Materials</i> , 2017, 29, 1702888.	11.1	38
610	Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions. <i>Molecular and Translational Medicine</i> , 2017, , 99-120.	0.4	1
611	Ficolin-2 triggers antitumor effect by activating macrophages and CD8 + T cells. <i>Clinical Immunology</i> , 2017, 183, 145-157.	1.4	12
612	Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway. <i>Onc Immunology</i> , 2017, 6, e1362527.	2.1	69
613	Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. <i>Cancer Science</i> , 2017, 108, 1959-1966.	1.7	61
614	Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. <i>Vaccine</i> , 2017, 35, 5842-5849.	1.7	17
615	Pro-inflammatory chitosan/poly(L-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity. <i>Acta Biomaterialia</i> , 2017, 63, 96-109.	4.1	45
616	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
617	Roles for Innate Immunity in Combination Immunotherapies. <i>Cancer Research</i> , 2017, 77, 5215-5221.	0.4	81
618	Bridging Bio-Nano Science and Cancer Nanomedicine. <i>ACS Nano</i> , 2017, 11, 9594-9613.	7.3	304
619	Serum amyloid A inhibits dendritic cell differentiation by suppressing GM-CSF receptor expression and signaling. <i>Experimental and Molecular Medicine</i> , 2017, 49, e369-e369.	3.2	9
620	Hematologic neoplasms: Dendritic cells vaccines in motion. <i>Clinical Immunology</i> , 2017, 183, 181-190.	1.4	17
621	The Role of Chemokines in Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 1347-1359.	2.4	37
622	SOCS1: Regulator of T Cells in Autoimmunity and Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 159-189.	0.7	18
623	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
624	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	180
625	Cytokine profiles of dendritic cells (DCs) during infection with bovine leukaemia virus (BLV). <i>Polish Journal of Veterinary Sciences</i> , 2017, 20, 221-231.	0.2	2

#	ARTICLE	IF	CITATIONS
626	An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. <i>Mathematical Biosciences</i> , 2017, 292, 1-9.	0.9	44
627	Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. <i>Immunology</i> , 2017, 152, 462-471.	2.0	20
628	Tumor-associated immune aggregates in oral cancer: Their cellular composition and potential prognostic significance. <i>Medical Hypotheses</i> , 2017, 108, 17-23.	0.8	6
629	Therapeutic blockade of Foxp3 in experimental breast cancer models. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 393-405.	1.1	21
630	Enhanced Visualization of Hematoxylin and Eosin Stained Pathological Characteristics by Phasor Approach. <i>Analytical Chemistry</i> , 2017, 89, 9224-9231.	3.2	23
631	A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response. <i>Scientific Reports</i> , 2017, 7, 6286.	1.6	46
632	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. <i>Journal of Radiation Research</i> , 2017, 58, 446-455.	0.8	44
633	A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2017, 25, 2299-2308.	3.7	21
634	Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.	1.3	84
635	Cancer Immunity and Immune Evasion Mechanisms. , 2017, , 195-220.		1
636	Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8 + Immunity In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 419-427.	2.3	9
638	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	1
639	Modulating host immune responses to fight invasive fungal infections. <i>Current Opinion in Microbiology</i> , 2017, 40, 95-103.	2.3	32
640	Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2931-2952.	1.4	14
641	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. <i>Cancer Immunology Research</i> , 2017, 5, 710-715.	1.6	36
642	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. <i>Cancer Cell</i> , 2017, 32, 42-56.e6.	7.7	1,282
643	Dendritic cell-based immunotherapy: a basic review and recent advances. <i>Immunologic Research</i> , 2017, 65, 798-810.	1.3	158
644	The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. <i>Oncot Immunology</i> , 2017, 6, e1253655.	2.1	50

#	ARTICLE	IF	CITATIONS
645	Ovarian Cancers. , 2017, , .		1
646	Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation. Human Vaccines and Immunotherapeutics, 2017, 13, 50-62.	1.4	52
647	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered, 2017, 8, 367-373.	1.4	7
648	Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. Journal of Pathology, 2017, 241, 10-24.	2.1	55
649	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. European Urology, 2017, 71, 854-857.	0.9	22
650	Considerations for successful cancer immunotherapy in aged hosts. Clinical and Experimental Immunology, 2017, 187, 53-63.	1.1	56
651	High-Grade Gliomas. Pediatric Oncology, 2017, , 37-50.	0.5	0
652	Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. Trends in Biotechnology, 2017, 35, 215-226.	4.9	77
653	Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro. Oncology Reports, 2018, 39, 1306-1312.	1.2	1
654	Progress in Vaccine Therapies for Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 315-330.	0.8	11
655	Hierarchically porous, and Cu- and Zn-containing $\beta$ -AlOOH mesostrands as adjuvants for cancer immunotherapy. Scientific Reports, 2017, 7, 16749.	1.6	27
656	Topically applied virus-like particles containing HIV-1 Pr55gag protein reach skin antigen-presenting cells after mild skin barrier disruption. Journal of Controlled Release, 2017, 268, 296-304.	4.8	6
657	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, , .	0.8	9
658	Tumor Immuno-Environment in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, 2017, 1036, 1-18.	0.8	31
659	The Role of Tumor Microenvironment in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 1036, 51-64.	0.8	124
660	miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38. Molecular Medicine Reports, 2017, 16, 1307-1313.	1.1	19
661	Complementing single-cell RNA-seq using bulk transcriptional profiles. , 2017, , .		2
663	Dendritic Cell Therapy for Brain Tumors. , 2017, , 301-321.		0

#	ARTICLE	IF	CITATIONS
664	Dendritic Cells in the Immune System-History, Lineages, Tissues, Tolerance, and Immunity. , 2017, , 155-207.		1
665	Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. <i>Frontiers in Pharmacology</i> , 2017, 8, 295.	1.6	74
666	Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma. <i>Theranostics</i> , 2017, 7, 2732-2745.	4.6	328
667	New Immunotherapy Strategies in Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 68.	1.2	76
668	The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 650.	1.8	20
669	Human Lung Mononuclear Phagocytes in Health and Disease. <i>Frontiers in Immunology</i> , 2017, 8, 499.	2.2	50
670	Intratumoral Lentivector-Mediated TGF- $\beta$ 1 Gene Downregulation As a Potent Strategy for Enhancing the Antitumor Effect of Therapy Composed of Cyclophosphamide and Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 713.	2.2	19
671	Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies. <i>Frontiers in Immunology</i> , 2017, 8, 1090.	2.2	40
672	Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1228.	2.2	165
673	Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression. <i>Frontiers in Immunology</i> , 2017, 8, 1724.	2.2	6
674	Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	22
675	Comparison of Myeloid Cells in Circulation and in the Tumor Microenvironment of Patients with Colorectal and Breast Cancers. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	10
676	Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	4
677	Advances in Immunotherapy for Glioblastoma Multiforme. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	73
678	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 191-197.	1.0	18
679	The current status of immunobased therapies for metastatic renal-cell carcinoma. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 83-93.	2.7	14
680	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. , 2017, , 119-135.		1
681	Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model. <i>PLoS ONE</i> , 2017, 12, e0178479.	1.1	112

#	ARTICLE	IF	CITATIONS
682	Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion. PLoS ONE, 2017, 12, e0184915.	1.1	1
683	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Systems Biology, 2017, 11, 70.	3.0	37
684	Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer. Oncology Letters, 2017, 15, 1297-1306.	0.8	6
685	Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. Current Cancer Drug Targets, 2017, 17, 1-1.	0.8	12
686	Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy. Oncotarget, 2017, 8, 5371-5381.	0.8	28
687	Immune Cells As Targets and Tools For Cancer Therapy. Immunotherapy (Los Angeles, Calif ), 2017, 03, .	0.1	0
688	Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia-Pacific Journal of Oncology Nursing, 2017, 4, 127-135.	0.7	156
689	Cancer Immunotherapy. , 2017, , 32-65.		1
690	Inflammasome in Dendritic Cells Immunobiology: Implications to Diseases and Therapeutic Strategies. Current Drug Targets, 2017, 18, 1003-1018.	1.0	12
691	The paradoxical role of tumor-infiltrating immune cells in lung cancer. Intractable and Rare Diseases Research, 2017, 6, 234-241.	0.3	27
692	Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen. OncoTargets and Therapy, 2017, Volume 10, 3979-3990.	1.0	7
693	Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40. Journal of Immunotherapy, 2017, 40, 39-50.	1.2	12
694	Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells. Current Stem Cell Research and Therapy, 2017, 12, 188-196.	0.6	10
695	Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. Oncotarget, 2017, 8, 81617-81635.	0.8	17
696	Antigen-Presenting Cell/Tumour Cell Hybrid Vaccines in Cancer Immunotherapy. , 2017, , .		1
697	Merits and complexities of modeling multiple sclerosis in non-human primates: implications for drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 387-397.	2.5	8
698	Nivolumab in the treatment of advanced renal cell carcinoma. Future Oncology, 2018, 14, 1679-1689.	1.1	3
699	Clec9A+ Dendritic Cells Are Not Essential for Antitumor CD8+ T Cell Responses Induced by Poly I:C Immunotherapy. Journal of Immunology, 2018, 200, 2978-2986.	0.4	15



#	ARTICLE	IF	CITATIONS
700	Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. <i>Cancer Letters</i> , 2018, 419, 210-221.	3.2	251
701	Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. <i>Immunotherapy</i> , 2018, 10, 373-382.	1.0	10
702	Mutual Destruction of Deep Lung Tumor Tissues by Nanodrug-Conjugated Stealth Mesenchymal Stem Cells. <i>Advanced Science</i> , 2018, 5, 1700860.	5.6	24
703	Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in $\text{in vitro}$ . <i>Oncology Letters</i> , 2018, 15, 5345-5351.	0.8	10
704	Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4453-E4462.	3.3	16
705	Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model. <i>Cancer Science</i> , 2018, 109, 956-965.	1.7	26
706	Nanoparticle-Based Phototriggered Cancer Immunotherapy and Its Domino Effect in the Tumor Microenvironment. <i>Biomacromolecules</i> , 2018, 19, 1869-1887.	2.6	64
707	Magnetic nanoparticles based cancer therapy: current status and applications. <i>Science China Life Sciences</i> , 2018, 61, 400-414.	2.3	74
708	Beyond migration-Chemokines in lymphocyte priming, differentiation, and modulating effector functions. <i>Journal of Leukocyte Biology</i> , 2018, 104, 301-312.	1.5	28
709	$\beta$ -Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation. <i>Oncolimmunology</i> , 2018, 7, e1450713.	2.1	8
710	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. <i>Small Methods</i> , 2018, 2, 1700347.	4.6	32
711	Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4032-E4040.	3.3	7
712	An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice. <i>Journal of Controlled Release</i> , 2018, 273, 1-12.	4.8	31
713	Targeting cancer stem cells in the clinic: Current status and perspectives. , 2018, 187, 13-30.		61
714	Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. <i>Translational Oncology</i> , 2018, 11, 250-258.	1.7	57
715	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	2.1	38
716	Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. <i>Cell Death and Disease</i> , 2018, 9, 115.	2.7	408
717	Expected Paradigm Shift in Brain Metastases Therapy—Immune Checkpoint Inhibitors. <i>Molecular Neurobiology</i> , 2018, 55, 7072-7078.	1.9	18



#	ARTICLE	IF	CITATIONS
718	SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 675-684.	1.2	13
719	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. <i>Nature Protocols</i> , 2018, 13, 335-357.	5.5	32
720	Antigen-Free Radionuclide-Embedded Gold Nanoparticles for Dendritic Cell Maturation, Tracking, and Strong Antitumor Immunity. <i>Advanced Healthcare Materials</i> , 2018, 7, e1701369.	3.9	20
721	Precision-porous templated scaffolds of varying pore size drive dendritic cell activation. <i>Biotechnology and Bioengineering</i> , 2018, 115, 1086-1095.	1.7	27
722	Recent challenges and advances in genetically-engineered cell therapy. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 199-208.	2.7	24
723	The Human Tumor Microenvironment. , 2018, , 5-21.		2
724	Challenges in Colorectal Cancer: From Vaccines to Macrophage Repolarization. , 2018, , 621-639.		0
725	Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies. <i>Translational Oncology</i> , 2018, 11, 132-139.	1.7	5
726	Role of immune system in tumor progression and carcinogenesis. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 5028-5042.	1.2	49
727	Current and emerging EGFR therapies for glioblastoma. <i>Journal of Immunoassay and Immunochemistry</i> , 2018, 39, 1-11.	0.5	5
728	Antigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immuno-therapy. <i>Advanced Materials</i> , 2018, 30, 1704408.	11.1	143
729	Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. <i>Biomaterials</i> , 2018, 159, 119-129.	5.7	132
730	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
731	Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment. <i>Journal of Translational Medicine</i> , 2018, 16, 89.	1.8	8
732	Neutrophil-Based Drug Delivery Systems. <i>Advanced Materials</i> , 2018, 30, e1706245.	11.1	236
733	Inflammation-on-a-Chip: Probing the Immune System Ex Vivo. <i>Trends in Biotechnology</i> , 2018, 36, 923-937.	4.9	55
734	Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. <i>Biomaterials</i> , 2018, 171, 198-206.	5.7	98
735	TK Inhibitor Pazopanib Primes DCs by Downregulation of the $\beta$ -Catenin Pathway. <i>Cancer Immunology Research</i> , 2018, 6, 711-722.	1.6	47

#	ARTICLE	IF	CITATIONS
736	Low-Dose Radiation Promotes Dendritic Cell Migration and IL-12 Production via the ATM/NF-KappaB Pathway. <i>Radiation Research</i> , 2018, 189, 409.	0.7	23
737	Aluminum hydroxide colloid vaccine encapsulated in yeast shells with enhanced humoral and cellular immune responses. <i>Biomaterials</i> , 2018, 167, 32-43.	5.7	31
738	Nanoparticles for dendritic cell-based immunotherapy. <i>International Journal of Pharmaceutics</i> , 2018, 542, 253-265.	2.6	61
739	A Tricin Derivative from <i>Deschampsia antarctica</i> Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 966-976.	1.9	21
740	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. <i>Annals of Oncology</i> , 2018, 29, 1312-1319.	0.6	106
741	Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 211-221.	0.6	21
742	The Role of Exosomes in Pancreatic Cancer Microenvironment. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 1111-1133.	0.9	36
743	Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 225-236.	2.0	5
744	Vaccination in the immunotherapy of glioblastoma. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 255-268.	1.4	50
745	Considerations for successful cancer immunotherapy in aged hosts. <i>Experimental Gerontology</i> , 2018, 107, 27-36.	1.2	33
746	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253
747	Overexpression of Notch ligand Delta-like-1 by dendritic cells enhances their immunoregulatory capacity and exerts antiallergic effects on Th2-mediated allergic asthma in mice. <i>Clinical Immunology</i> , 2018, 187, 58-67.	1.4	14
748	Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients. <i>Clinical Otolaryngology</i> , 2018, 43, 463-469.	0.6	20
749	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. <i>OncImmunology</i> , 2018, 7, e1372081.	2.1	37
750	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. <i>Cancer Research</i> , 2018, 78, 463-474.	0.4	70
751	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	10.6	736
752	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. <i>Clinical Cancer Research</i> , 2018, 24, 766-776.	3.2	68
753	Metallic nanoparticles for cancer immunotherapy. <i>Materials Today</i> , 2018, 21, 673-685.	8.3	164

#	ARTICLE	IF	CITATIONS
754	Natural Compounds as Epigenetic Regulators of Human Dendritic Cell-mediated Immune Function. <i>Journal of Immunotherapy</i> , 2018, 41, 169-180.	1.2	8
755	Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. <i>Oncolmunology</i> , 2018, 7, e1395126.	2.1	24
756	Combination immunotherapy and radiation therapy strategies for pancreatic cancerâ€”targeting multiple steps in the cancer immunity cycle. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1014-1026.	0.6	42
758	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0
759	Cytokine-induced killer cell/dendritic cellâ€”cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer. <i>Medicine (United States)</i> , 2018, 97, e12230.	0.4	14
760	New Strategies to Improve Therapeutic Vaccines. , 0, , .		1
761	An Overview of Cancer Treatment Modalities. , 0, , .		72
762	Dendritic Cell Subsets, Maturation and Function. , 0, , .		7
763	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
764	Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. <i>Journal of Immunology Research</i> , 2018, 2018, 1-12.	0.9	11
765	Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 3059.	2.2	354
766	The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy. <i>Frontiers in Medicine</i> , 2018, 5, 337.	1.2	2
767	Addressing cancer immunotherapy research in Iran: adoptive cell therapy on the horizon. <i>Cytotherapy</i> , 2018, 20, 1227-1237.	0.3	2
768	FoxN1-dependent thymic epithelial cells promote T-cell leukemia development. <i>Carcinogenesis</i> , 2018, 39, 1463-1476.	1.3	11
769	Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10. <i>Frontiers in Immunology</i> , 2018, 9, 1923.	2.2	17
770	A systematic electron microscopic study on the uptake of barium sulphate nano-, submicro-, microparticles by bone marrow-derived phagocytosing cells. <i>Acta Biomaterialia</i> , 2018, 80, 352-363.	4.1	9
771	Drug resistance and new therapies in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3834-3848.	1.4	406
772	Nanoparticleâ€”Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses. <i>Advanced Materials</i> , 2018, 30, e1803397.	11.1	120

#	ARTICLE	IF	CITATIONS
773	Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphilesâ€“TLR7/8 Agonist Conjugates. <i>Journal of the American Chemical Society</i> , 2018, 140, 14300-14307.	6.6	50
774	In situ administration of cytokine combinations induces tumor regression in mice. <i>EBioMedicine</i> , 2018, 37, 38-46.	2.7	10
775	Biomaterials for vaccine-based cancer immunotherapy. <i>Journal of Controlled Release</i> , 2018, 292, 256-276.	4.8	146
776	Targeted Theranostic Nanoparticles for Brain Tumor Treatment. <i>Pharmaceutics</i> , 2018, 10, 181.	2.0	85
777	Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity. <i>Journal of Immunology</i> , 2018, 201, 3383-3391.	0.4	13
778	GM-CSF Culture Revisited: Preparation of Bulk Populations of Highly Pure Dendritic Cells from Mouse Bone Marrow. <i>Journal of Immunology</i> , 2018, 201, 3129-3139.	0.4	21
779	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1092, 113-138.	0.8	19
780	Radiogenomics Profiling for Glioblastoma-related Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis. <i>Scientific Reports</i> , 2018, 8, 16022.	1.6	25
781	Co-culture of dendritic cells and cytokine-induced killer cells effectively suppresses liver cancer stem cell growth by inhibiting pathways in the immune system. <i>BMC Cancer</i> , 2018, 18, 984.	1.1	34
782	Combined encapsulation of a tumor antigen and immune cells using a self-assembling immunostimulatory DNA hydrogel to enhance antigen-specific tumor immunity. <i>Journal of Controlled Release</i> , 2018, 288, 189-198.	4.8	25
783	Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2018, 8, 404.	1.3	113
784	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. <i>Journal of Controlled Release</i> , 2018, 289, 125-145.	4.8	31
785	Uncovering the underlying physical mechanism for cancer-immunity of MHC class I diversity. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 532-537.	1.0	3
786	Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 302.	1.7	94
787	An overview of cancer immunotherapeutic strategies. <i>Immunotherapy</i> , 2018, 10, 999-1010.	1.0	26
788	Genetically-encoded fragment-based discovery of glycopeptide ligands for DC-SIGN. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5368-5377.	1.4	19
789	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 293.	0.7	27
790	Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1777-1788.	2.0	67

#	ARTICLE	IF	CITATIONS
791	Evaluating intrinsic and non-intrinsic cancer risk factors. <i>Nature Communications</i> , 2018, 9, 3490.	5.8	218
792	Injectable Hydrogels Coencapsulating Granulocyte-Macrophage Colony-Stimulating Factor and Ovalbumin Nanoparticles to Enhance Antigen Uptake Efficiency. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 20315-20325.	4.0	48
793	Exosomes, Stem Cells and MicroRNA. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	1
794	Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. <i>ACS Nano</i> , 2018, 12, 5121-5129.	7.3	505
795	Evaluating dendritic cells as an in vitro screening tool for immunotherapeutic formulations. <i>Journal of Immunological Methods</i> , 2018, 459, 55-62.	0.6	4
796	Profiling dendritic cell subsets in head and neck squamous cell tonsillar cancer and benign tonsils. <i>Scientific Reports</i> , 2018, 8, 8030.	1.6	13
798	Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways. <i>BioMed Research International</i> , 2018, 2018, 1-15.	0.9	45
799	Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis. <i>Prostate International</i> , 2018, 6, 119-125.	1.2	6
801	Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. <i>International Immunopharmacology</i> , 2018, 61, 363-375.	1.7	18
802	Dendritic cell trafficking in tumor-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1939-1947.	2.0	10
803	Overview of Dendritic Cell Vaccines for Brain Tumors. , 2018, , 681-692.		0
804	Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. <i>Oncology Letters</i> , 2018, 16, 1348-1356.	0.8	9
805	Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity. <i>Nano Letters</i> , 2018, 18, 4377-4385.	4.5	147
806	Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2018, 2018, 1-15.	0.9	7
807	Therapeutic potential of the vagus nerve in cancer. <i>Immunology Letters</i> , 2018, 202, 38-43.	1.1	34
808	Distinct features of dendritic cell-based immunotherapy as cancer vaccines. <i>Clinical and Experimental Vaccine Research</i> , 2018, 7, 16.	1.1	14
809	Nanoimmunotherapy "cloaked defenders to breach the cancer fortress. <i>Nanotechnology Reviews</i> , 2018, 7, 317-340.	2.6	8
810	Antitumor efficacy of the Runx2-pulsed dendritic cell vaccine in triple-negative breast cancer in vitro. <i>Oncology Letters</i> , 2018, 16, 2813-2822.	0.8	9

#	ARTICLE	IF	CITATIONS
811	Advances in the Delivery of Cancer Therapeutics: A Comprehensive Review. <i>Current Drug Delivery</i> , 2018, 15, 21-36.	0.8	15
812	Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer. <i>Oral Oncology</i> , 2018, 84, 61-70.	0.8	16
813	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 14.	2.2	356
814	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. <i>Frontiers in Immunology</i> , 2018, 9, 610.	2.2	46
815	Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation. <i>Frontiers in Immunology</i> , 2018, 9, 892.	2.2	18
816	Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 982.	2.2	11
817	Blockade of MIFâ€“CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1132.	2.2	109
818	Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability. <i>Frontiers in Immunology</i> , 2018, 9, 1328.	2.2	12
819	Polymer nanoparticles as adjuvants in cancer immunotherapy. <i>Nano Research</i> , 2018, 11, 5769-5786.	5.8	66
820	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	1.8	376
821	Chronic Sleep Restriction Impairs the Antitumor Immune Response in Mice. <i>NeuroImmunoModulation</i> , 2018, 25, 59-67.	0.9	29
822	Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1461-1472.	2.0	68
823	Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth. <i>Cancer Immunology Research</i> , 2018, 6, 953-964.	1.6	25
824	The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. <i>Theranostics</i> , 2018, 8, 1723-1739.	4.6	71
825	Exosome-Based Cell-Cell Communication in the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 18.	1.8	495
826	Exosomes Function in Tumor Immune Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1056, 109-122.	0.8	36
827	Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipptide vaccines: a case report. <i>Journal of Translational Medicine</i> , 2018, 16, 23.	1.8	30
828	Construction and Characterization of Adenovirus Vectors Encoding Aspartate-<sup>2</sup>-Hydroxylase to Preliminary Application in Immunotherapy of Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	4

#	ARTICLE	IF	CITATIONS
829	Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles. <i>Advanced Therapeutics</i> , 2018, 1, 1800065.	1.6	52
830	Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. <i>Onc Immunology</i> , 2018, 7, e1477459.	2.1	37
831	Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma. <i>International Immunopharmacology</i> , 2018, 64, 69-77.	1.7	9
832	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
833	Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1787.	2.2	33
834	Dendritic cells pulsed with generated tumor cell lysate from <i>Phyllanthus amarus</i> Schum. & Thonn. induces anti-tumor immune response. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 232.	3.7	9
835	PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression. <i>Cancer Cell International</i> , 2018, 18, 112.	1.8	49
836	Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent <i>In Vitro</i> Activation with Tumor Immune Complexes. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	2
837	Computational morphogenesis – Embryogenesis, cancer research and digital pathology. <i>BioSystems</i> , 2018, 169-170, 40-54.	0.9	11
838	Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. <i>Immunology Letters</i> , 2018, 200, 33-42.	1.1	19
839	Deprotection-Induced Morphology Transition and Immunoactivation of Glycovesicles: A Strategy of Smart Delivery Polymersomes. <i>Journal of the American Chemical Society</i> , 2018, 140, 8851-8857.	6.6	47
840	Recent advancement in cancer treatment. , 2018, , 621-651.		1
841	Durch Nanopartikel vermittelter immunogener Zelltod ermöglicht und verstärkt die Immuntherapie gegen Krebs. <i>Angewandte Chemie</i> , 2019, 131, 680-691.	1.6	22
842	Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 670-680.	7.2	671
843	The role of dendritic cells in cancer. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 123-178.	1.6	110
844	Screening and Identification of a Chicken Dendritic Cell Binding Peptide by Using a Phage Display Library. <i>Frontiers in Immunology</i> , 2019, 10, 1853.	2.2	16
845	Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1129-1137.	2.8	84
846	Membrane-encapsulated camouflaged nanomedicines in drug delivery. <i>Nanomedicine</i> , 2019, 14, 2067-2082.	1.7	28



#	ARTICLE	IF	CITATIONS
847	Trial watch: dendritic cell vaccination for cancer immunotherapy. <i>Oncolimmunology</i> , 2019, 8, 1638212.	2.1	125
848	STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	0.9	11
849	Anti-cervical carcinoma effect of <i>Portulaca oleracea</i> L. polysaccharides by oral administration on intestinal dendritic cells. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 161.	3.7	15
850	DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. <i>Acta Biomaterialia</i> , 2019, 96, 480-490.	4.1	64
851	Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects. <i>Cancer Research and Treatment</i> , 2019, 51, 464-473.	1.3	15
852	Oneâ€Pot, Multicomponent Strategy for Designing Lymphoseekâ€Inspired Heteroâ€Glycoadjuvant@AuNPs. <i>Macromolecular Rapid Communications</i> , 2019, 40, 1900215.	2.0	3
853	Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2â€RhoAâ€cofilin1 pathway. <i>Cancer Science</i> , 2019, 110, 2357-2367.	1.7	44
854	Influenza mimetic proteinâ€polymer nanoparticles as antigen delivery vehicles to dendritic cells for cancer immunotherapy. <i>Nanoscale</i> , 2019, 11, 13878-13884.	2.8	10
855	Single-Cell Omics for Drug Discovery and Development. , 2019, , 197-220.		0
856	Nanomedicineâ€Based Immunotherapy for the Treatment of Cancer Metastasis. <i>Advanced Materials</i> , 2019, 31, e1904156.	11.1	120
857	Mathematical modelling of cancer stem cell-targeted immunotherapy. <i>Mathematical Biosciences</i> , 2019, 318, 108269.	0.9	18
858	Expansion processes for cell-based therapies. <i>Biotechnology Advances</i> , 2019, 37, 107455.	6.0	15
859	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. <i>Biomedicines</i> , 2019, 7, 80.	1.4	0
860	Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells. <i>Cancers</i> , 2019, 11, 1491.	1.7	20
861	A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures. <i>Nature Communications</i> , 2019, 10, 4808.	5.8	44
862	Current clinical management of patients with glioblastoma. <i>Cancer Reports</i> , 2019, 2, e1216.	0.6	11
863	The role of the innate and adaptive immune response in HPVâ€associated oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 508-512.	0.6	10
864	Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics. <i>Cells</i> , 2019, 8, 1380.	1.8	76

#	ARTICLE	IF	CITATIONS
865	Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer. <i>ACS Nano</i> , 2019, 13, 12511-12524.	7.3	110
866	Dual oxidase 1 and NADPH oxidase 2 exert favorable effects in cervical cancer patients by activating immune response. <i>BMC Cancer</i> , 2019, 19, 1078.	1.1	16
867	Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer. <i>Small</i> , 2019, 15, e1903881.	5.2	124
868	Surface-Layer Protein-Enhanced Immunotherapy Based on Cell Membrane-Coated Nanoparticles for the Effective Inhibition of Tumor Growth and Metastasis. <i>ACS Applied Materials &amp; Interfaces</i> , 2019, 11, 9850-9859.	4.0	73
869	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
870	Human CD141+ dendritic cells generated from adult peripheral blood monocytes. <i>Cytotherapy</i> , 2019, 21, 1049-1063.	0.3	10
871	Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. <i>Journal of Materials Chemistry B</i> , 2019, 7, 6321-6346.	2.9	26
872	Chitosan/calcium phosphates nanosheet as a vaccine carrier for effective cross-presentation of exogenous antigens. <i>Carbohydrate Polymers</i> , 2019, 224, 115172.	5.1	26
873	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118636.	2.6	24
874	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
875	Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353.	2.2	22
876	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	5.6	80
877	Immune Check Point CD40/CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells. <i>Anticancer Research</i> , 2019, 39, 4643-4652.	0.5	4
878	Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer. <i>Nutrients</i> , 2019, 11, 2264.	1.7	85
879	In situ thermal ablation of tumors in combination with nano-adjuvant and immune checkpoint blockade to inhibit cancer metastasis and recurrence. <i>Biomaterials</i> , 2019, 224, 119490.	5.7	59
880	Novel fusion cells derived from tumor cells expressing the heterologous $\beta$ -galactose epitope and dendritic cells effectively target cancer. <i>Vaccine</i> , 2019, 37, 926-936.	1.7	2
881	Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 134.	1.0	6
882	A 3D Macroporous Alginate Graphene Scaffold with an Extremely Slow Release of a Loaded Cargo for In Situ Long-Term Activation of Dendritic Cells. <i>Advanced Healthcare Materials</i> , 2019, 8, e1800571.	3.9	27

#	ARTICLE	IF	CITATIONS
883	Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells. <i>Cancers</i> , 2019, 11, 108.	1.7	3
884	Understanding the Anti-Tumor Properties Mediated by the Synthetic Peptide GK-1. , 2019, , .		0
885	Immunotherapy in myeloma: how far have we come?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882266.	1.1	47
886	Hypoxia and the Tumor Secretome. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1136, 57-69.	0.8	11
887	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. <i>Nano Today</i> , 2019, 27, 28-47.	6.2	34
888	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. <i>Journal of Controlled Release</i> , 2019, 307, 108-138.	4.8	49
889	Type I interferons and dendritic cells in cancer immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, 217-262.	1.6	81
890	Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions. <i>Immunobiology</i> , 2019, 224, 697-705.	0.8	25
891	Towards Immunotherapy for Pediatric Brain Tumors. <i>Trends in Immunology</i> , 2019, 40, 748-761.	2.9	77
892	Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	15
893	The 100 top-cited studies in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2282-2292.	1.9	26
894	Mannoseâ€Modified Serum Exosomes for the Elevated Uptake to Murine Dendritic Cells and Lymphatic Accumulation. <i>Macromolecular Bioscience</i> , 2019, 19, e1900042.	2.1	70
895	Hyaluronidase with pHâ€responsive Dextran Modification as an Adjuvant Nanomedicine for Enhanced Photodynamicâ€Immunotherapy of Cancer. <i>Advanced Functional Materials</i> , 2019, 29, 1902440.	7.8	156
896	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
897	Roles of exosomes in liver metastases: Novel diagnosis and treatment choices. <i>Journal of Cellular Physiology</i> , 2019, 234, 21588-21600.	2.0	13
898	The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 115, 108952.	2.5	25
899	Photothermal/Photodynamic Therapy with Immuneâ€Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy. <i>Particle and Particle Systems Characterization</i> , 2019, 36, 1900015.	1.2	20
900	Tumour microenvironment responsive nanoconstructs for cancer theranostic. <i>Nano Today</i> , 2019, 26, 16-56.	6.2	113

#	ARTICLE	IF	CITATIONS
901	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
902	An optimized protocol to determine the engulfment of cancer cells by phagocytes using flow cytometry and fluorescence microscopy. <i>Journal of Immunological Methods</i> , 2019, 470, 27-32.	0.6	16
903	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 579.	1.0	48
904	Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration. <i>RSC Advances</i> , 2019, 9, 11230-11238.	1.7	81
905	Beyond the tumour microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 2611-2618.	2.3	71
906	Non-viral gene delivery for cancer immunotherapy. <i>Journal of Gene Medicine</i> , 2019, 21, e3092.	1.4	22
907	How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?. <i>BMC Systems Biology</i> , 2019, 13, 30.	3.0	17
908	Synthetic, Supramolecular, and Self-Adjuvanting CD8 <sup>+</sup> T Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity. <i>Advanced Therapeutics</i> , 2019, 2, 1900010.	1.6	15
909	Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 350.	1.0	47
910	Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. <i>EBioMedicine</i> , 2019, 42, 281-295.	2.7	94
911	<i>In Situ</i> Dendritic Cell Vaccine for Effective Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 3083-3094.	7.3	164
912	Exposure to Low-Dose Radiation Enhanced the Antitumor Effect of a Dendritic Cell Vaccine. Dose-Response, 2019, 17, 155932581983214.	0.7	5
913	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
914	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. <i>Advanced Materials</i> , 2019, 31, e1808303.	11.1	223
915	Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. <i>European Journal of Pharmacology</i> , 2019, 852, 231-243.	1.7	33
916	Therapeutic targeting of trained immunity. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 553-566.	21.5	287
917	Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon $\gamma$ production. <i>Cytotherapy</i> , 2019, 21, 643-658.	0.3	7
918	HPMA-Based Nanocarriers for Effective Immune System Stimulation. <i>Macromolecular Bioscience</i> , 2019, 19, e1800481.	2.1	21

#	ARTICLE	IF	CITATIONS
919	Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells. <i>Frontiers in Immunology</i> , 2019, 10, 931.	2.2	15
920	A core-shell polymeric-inorganic hybrid nanocomposite system for MRI-visible gene delivery application in cancer immunotherapy. <i>Journal of Industrial and Engineering Chemistry</i> , 2019, 76, 188-196.	2.9	17
921	Oxymatrine-mediated maturation of dendritic cells leads to activation of FOXP3+/CD4+ Treg cells and reversal of cisplatin-resistance in lung cancer cells. <i>Molecular Medicine Reports</i> , 2019, 19, 4081-4090.	1.1	6
922	Shikimoyl-ligand decorated gold nanoparticles for use in <i>in vivo</i> engineered dendritic cell based DNA vaccination. <i>Nanoscale</i> , 2019, 11, 7931-7943.	2.8	45
923	Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results. <i>Frontiers in Immunology</i> , 2019, 10, 766.	2.2	132
924	Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2019, 10, 467.	2.2	122
925	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
926	Immunotherapy for Neuroblastoma. , 2019, , 147-173.		4
927	TLR4 signaling improves PD-1 blockade therapy during chronic viral infection. <i>PLoS Pathogens</i> , 2019, 15, e1007583.	2.1	17
928	Dendritic Cell Targeting Peptide-Based Nanovaccines for Enhanced Cancer Immunotherapy. <i>ACS Applied Bio Materials</i> , 2019, 2, 1241-1254.	2.3	18
929	Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation. <i>Frontiers in Immunology</i> , 2018, 9, 3109.	2.2	26
930	Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors?. <i>Molecular Immunology</i> , 2019, 108, 102-110.	1.0	20
931	Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. <i>Oncotmmunology</i> , 2019, 8, e1568809.	2.1	22
932	Re-evaluation of the linear no-threshold (LNT) model using new paradigms and modern molecular studies. <i>Chemico-Biological Interactions</i> , 2019, 301, 54-67.	1.7	45
933	Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. <i>Cardiovascular Research</i> , 2019, 115, 949-959.	1.8	38
934	Cancer Vaccines. , 2019, , .		1
935	Ex vivo dendritic cell generation—A critical comparison of current approaches. <i>International Review of Cell and Molecular Biology</i> , 2019, 349, 251-307.	1.6	13
936	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. <i>Frontiers in Immunology</i> , 2019, 10, 2393.	2.2	92

#	ARTICLE	IF	CITATIONS
937	Prefaceâ€”Dendritic cells: Master regulators of innate and adaptive immunity. <i>International Review of Cell and Molecular Biology</i> , 2019, 348, ix-xiv.	1.6	2
938	Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant. <i>Nanoscale</i> , 2019, 11, 21782-21789.	2.8	43
939	Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1208.	1.3	43
940	Transcriptional control of dendritic cell development and functions. <i>International Review of Cell and Molecular Biology</i> , 2019, 349, 55-151.	1.6	63
941	Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	2
942	Preface: Dendritic cells: Master regulators of innate and adaptive immunity. <i>International Review of Cell and Molecular Biology</i> , 2019, 349, xi-xvi.	1.6	1
943	Melanoma vaccines: clinical status and immune endpoints. <i>Melanoma Research</i> , 2019, 29, 109-118.	0.6	19
944	Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. <i>Frontiers in Immunology</i> , 2019, 10, 2876.	2.2	60
945	Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN <sup>®</sup> in combination with chemotherapy. <i>Future Science OA</i> , 2019, 5, FSO435.	0.9	3
946	A cycle involving HMGB1, IFN- $\gamma$ and dendritic cells plays a putative role in anti-tumor immunity. <i>Cellular Immunology</i> , 2019, 343, 103850.	1.4	17
947	WNT Signaling in Cancer Immunosurveillance. <i>Trends in Cell Biology</i> , 2019, 29, 44-65.	3.6	168
948	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 126-151.	4.6	128
949	Hypoxia-Triggered Transforming Immunomodulator for Cancer Immunotherapy via Photodynamically Enhanced Antigen Presentation of Dendritic Cell. <i>ACS Nano</i> , 2019, 13, 476-488.	7.3	113
950	Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 85, 1-26.	4.1	142
951	Maturation of dendritic cells by maitake $\beta$ -glucan enhances anti-cancer effect of dendritic cell vaccination. <i>International Immunopharmacology</i> , 2019, 67, 408-416.	1.7	20
952	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. <i>Advanced Functional Materials</i> , 2019, 29, 1806087.	7.8	21
953	Jagged1-expressing adenovirus-infected dendritic cells induce expansion of Foxp3 <sup>+</sup> regulatory T cells and alleviate T helper type 2-mediated allergic asthma in mice. <i>Immunology</i> , 2019, 156, 199-212.	2.0	31
954	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 326-335.	1.7	14

#	ARTICLE	IF	CITATIONS
955	Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs. <i>Journal of Theoretical Biology</i> , 2019, 462, 490-498.	0.8	27
956	Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances. <i>Journal of Controlled Release</i> , 2019, 297, 79-90.	4.8	59
957	The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	22
958	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
959	Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155. <i>Life Sciences</i> , 2019, 219, 152-162.	2.0	53
960	mRNA as novel technology for passive immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 301-328.	2.4	88
961	Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. <i>Biomaterials</i> , 2019, 190-191, 111-120.	5.7	43
962	Clinical immunotherapeutic approaches for the treatment of head and neck cancer. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2019, 48, 419-436.	0.7	10
963	Nanomedicine and macroscale materials in immuno-oncology. <i>Chemical Society Reviews</i> , 2019, 48, 351-381.	18.7	118
964	Exosomes: fighting cancer with cancer. <i>Therapeutic Delivery</i> , 2019, 10, 37-61.	1.2	22
965	Rational combination immunotherapeutic approaches for effective cancer treatment. <i>Journal of Controlled Release</i> , 2019, 294, 114-130.	4.8	28
966	Dendritic Cells in Hematopoietic Cell Transplantation. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 201-218.	0.0	0
967	CD8 <sup>+</sup> cytotoxic T lymphocytes in cancer immunotherapy: A review. <i>Journal of Cellular Physiology</i> , 2019, 234, 8509-8521.	2.0	1,012
968	Decreased RORC expression and downstream signaling in HTLV-1-associated adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?. <i>International Journal of Cancer</i> , 2019, 144, 1664-1675.	2.3	13
969	Phase I/II clinical trial of a Wilms <sup>™</sup> tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 121-130.	2.0	64
970	An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 71-83.	2.0	23
971	Targeting myeloid cells in the tumor sustaining microenvironment. <i>Cellular Immunology</i> , 2019, 343, 103713.	1.4	89
972	The expanding role of innate lymphoid cells and their T-cell counterparts in gastrointestinal cancers. <i>Molecular Immunology</i> , 2019, 110, 48-56.	1.0	15



#	ARTICLE	IF	CITATIONS
973	Dendritic cells as cancer therapeutics. <i>Seminars in Cell and Developmental Biology</i> , 2019, 86, 77-88.	2.3	50
974	Dysfunction of antigen processing and presentation by dendritic cells in cancer. <i>Molecular Immunology</i> , 2019, 113, 31-37.	1.0	75
975	Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 742-755.	1.4	3
976	Immunotherapies. , 2020, , 419-438.		1
977	BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2643-2654.	1.2	22
978	Cell transfer-based immunotherapies in cancer: A review. <i>IUBMB Life</i> , 2020, 72, 790-800.	1.5	12
979	Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy. <i>Stem Cells</i> , 2020, 38, 67-79.	1.4	22
980	Blockage of immune checkpoint molecules increases T cell priming potential of dendritic cell vaccine. <i>Immunology</i> , 2020, 159, 75-87.	2.0	67
981	HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 2.	1.0	54
982	The Immunotherapeutic Effect of SIRP±-Silenced DCs against Cervical Cancer. <i>Journal of Immunology Research</i> , 2020, 2020, 1-8.	0.9	0
983	Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody Recruitment. <i>Biomacromolecules</i> , 2020, 21, 793-802.	2.6	24
984	Synthetic 3D scaffolds for cancer immunotherapy. <i>Current Opinion in Biotechnology</i> , 2020, 65, 1-8.	3.3	6
985	Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 135-145.	2.0	42
986	Targeting Tumor Microenvironment by Small-Molecule Inhibitors. <i>Translational Oncology</i> , 2020, 13, 57-69.	1.7	82
987	Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies. <i>Cancers</i> , 2020, 12, 69.	1.7	16
988	Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment. <i>Cells</i> , 2020, 9, 33.	1.8	16
989	Microalgae with Immunomodulatory Activities. <i>Marine Drugs</i> , 2020, 18, 2.	2.2	91
990	Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. <i>Frontiers in Immunology</i> , 2020, 11, 568759.	2.2	79

#	ARTICLE	IF	CITATIONS
991	Huaier Extractum Promotes Dendritic Cells Maturation and Favors them to Induce Th1 Immune Response: One of the Mechanisms Underlying Its Anti-Tumor Activity. Integrative Cancer Therapies, 2020, 19, 153473542094683.	0.8	7
993	Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy. ACS Omega, 2020, 5, 22840-22846.	1.6	9
994	Combination of tumor fragments and nanotechnology as a therapeutic approach: Treating a tumor with tumor. Nano Today, 2020, 35, 100993.	6.2	21
995	Recent advances of GOLM1 in hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP22.	4.2	11
996	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663.	2.0	24
997	Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy. Translational Lung Cancer Research, 2020, 9, 2097-2112.	1.3	5
998	Clinical implication of cellular vaccine in glioma: current advances and future prospects. Journal of Experimental and Clinical Cancer Research, 2020, 39, 257.	3.5	31
999	Vİ39İ3İ T Cell Induction by Human Umbilical Cord Blood Monocytes-Derived, Interferon-Î±-Stimulated Dendritic Cells. Cancer Control, 2020, 27, 107327482097402.	0.7	1
1000	Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3. Frontiers in Microbiology, 2020, 11, 559105.	1.5	5
1001	Necroptosis in Immuno-Oncology and Cancer Immunotherapy. Cells, 2020, 9, 1823.	1.8	109
1002	Immunological dynamics after subcutaneous immunization with a squaleneâ€based oilâ€inâ€water adjuvant. FASEB Journal, 2020, 34, 12406-12418.	0.2	11
1003	Cell and tissue engineering in lymph nodes for cancer immunotherapy. Advanced Drug Delivery Reviews, 2020, 161-162, 42-62.	6.6	43
1004	Harnessing the Therapeutic Potential of Dendritic Cells. , 2020, , 489-505.		0
1005	Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. Frontiers in Immunology, 2020, 11, 594609.	2.2	66
1006	Enhanced antitumor efficacy through microwave ablation combined with a dendritic cell-derived exosome vaccine in hepatocellular carcinoma. International Journal of Hyperthermia, 2020, 37, 1210-1218.	1.1	23
1007	A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis. Science Advances, 2020, 6, .	4.7	95
1008	Preparation, Supramolecular Aggregation and Immunological Activity of the Bona Fide Vaccine Adjuvant Sulfavant S. Marine Drugs, 2020, 18, 451.	2.2	8
1009	Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response. Oncolmmunology, 2020, 9, 1814620.	2.1	13

#	ARTICLE	IF	CITATIONS
1010	Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. <i>Frontiers in Immunology</i> , 2020, 11, 1981.	2.2	9
1011	Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	2
1012	Immune-Based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. <i>HemaSphere</i> , 2020, 4, e423.	1.2	4
1014	Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the <sc>l</sc>-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade. <i>ACS Applied Materials &amp; Interfaces</i> , 2020, 12, 41127-41137.	4.0	19
1015	Maturation of Monocyte-Derived DCs Leads to Increased Cellular Stiffness, Higher Membrane Fluidity, and Changed Lipid Composition. <i>Frontiers in Immunology</i> , 2020, 11, 590121.	2.2	24
1016	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
1017	Nanostructured lipid carrier delivering chlorins e6 as in situ dendritic cell vaccine for immunotherapy of gastric cancer. <i>Journal of Materials Research</i> , 2020, 35, 3257-3264.	1.2	6
1018	Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. , 2020, 8, e000826.		74
1019	Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 986-994.	2.8	93
1020	Combination Therapy of Pulsed-Wave Ultrasound Hyperthermia and Immunostimulant OK-432 Enhances Systemic Antitumor Immunity for Cancer Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 140-149.	0.4	3
1021	Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. <i>Cancer Gene Therapy</i> , 2020, 27, 854-868.	2.2	19
1022	&lt;p&gt;MicroRNA-155 Suppresses the Translation of p38 and Impairs the Functioning of Dendritic Cells in Endometrial Cancer Mice&lt;p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 2993-3002.	0.9	8
1023	Protein-Based Artificial Nanosystems in Cancer Therapy. <i>Small</i> , 2020, 16, 1907256.	5.2	42
1024	A covalent organic framework as a nanocarrier for synergistic phototherapy and immunotherapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5451-5459.	2.9	56
1025	Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. , 2020, 8, e000368.		8
1026	Construction of microneedle-assisted co-delivery platform and its combining photodynamic/immunotherapy. <i>Journal of Controlled Release</i> , 2020, 324, 218-227.	4.8	66
1027	Label-Free, High-Throughput Assay of Human Dendritic Cells from Whole-Blood Samples with Microfluidic Inertial Separation Suitable for Resource-Limited Manufacturing. <i>Micromachines</i> , 2020, 11, 514.	1.4	11
1028	Engineered biomaterials for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 35-46.	3.1	52

#	ARTICLE	IF	CITATIONS
1029	Engineering Polymeric Prodrug Nanoplatfor for Vaccination Immunotherapy of Cancer. Nano Letters, 2020, 20, 4393-4402.	4.5	93
1030	Innate and Adaptive Immunity. , 2020, , 747-775.		8
1031	Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy. Chemical Engineering Journal, 2020, 399, 125854.	6.6	29
1032	Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092203.	1.4	42
1033	Annona muricata L-Derived Polysaccharides as a Potential Adjuvant to a Dendritic Cell-Based Vaccine in a Thymoma-Bearing Model. Nutrients, 2020, 12, 1602.	1.7	7
1034	Photosensitizer-Modified MnO <sub>2</sub> Nanoparticles to Enhance Photodynamic Treatment of Abscesses and Boost Immune Protection for Treated Mice. Small, 2020, 16, e2000589.	5.2	82
1035	Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity. Pharmaceutics, 2020, 12, 256.	2.0	56
1036	Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes. Immunological Reviews, 2020, 295, 203-219.	2.8	25
1037	Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism. International Immunopharmacology, 2020, 82, 106357.	1.7	11
1038	Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses. Frontiers in Immunology, 2020, 11, 327.	2.2	7
1039	Dendritic cell vaccine for the effective immunotherapy of breast cancer. Biomedicine and Pharmacotherapy, 2020, 126, 110046.	2.5	26
1040	Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death. ACS Applied Materials & Interfaces, 2020, 12, 16018-16030.	4.0	84
1041	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa031.	0.4	8
1042	<i>Ex vivo</i> -generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. Immunotherapy, 2020, 12, 333-349.	1.0	12
1043	Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Cancer Immunology Research, 2020, 8, 632-647.	1.6	42
1044	Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma. Cancers, 2020, 12, 545.	1.7	27
1045	Nanotechnologies for enhancing cancer immunotherapy. Nano Research, 2020, 13, 2595-2616.	5.8	22
1046	The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells. Frontiers in Immunology, 2020, 11, 1267.	2.2	10

#	ARTICLE	IF	CITATIONS
1047	A TCM Formula YYWY Inhibits Tumor Growth in Non-Small Cell Lung Cancer and Enhances Immune-Response Through Facilitating the Maturation of Dendritic Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 798.	1.6	20
1048	Update on glioma biotechnology. <i>Clinical Neurology and Neurosurgery</i> , 2020, 195, 106075.	0.6	4
1049	Carbosilane dendrimers: Drug and gene delivery applications. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 59, 101879.	1.4	52
1050	Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. <i>Journal of Controlled Release</i> , 2020, 326, 297-309.	4.8	66
1051	<i>In situ</i> self-assembly of conjugated polyelectrolytes for cancer targeted imaging and photodynamic therapy. <i>Biomaterials Science</i> , 2020, 8, 2156-2163.	2.6	25
1052	Tumor Microenvironments in Organs. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	2
1053	Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli—an Industry Perspective. <i>Advanced Science</i> , 2020, 7, 1903394.	5.6	40
1054	A preview of selected articles. <i>Stem Cells</i> , 2020, 38, 1-3.	1.4	0
1055	Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor. <i>Science China Mathematics</i> , 2020, 63, 465-484.	0.8	10
1056	Advanced biomaterials for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 911-927.	2.8	62
1057	Single-cell analysis targeting the proteome. <i>Nature Reviews Chemistry</i> , 2020, 4, 143-158.	13.8	157
1058	Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 779-788.	2.0	11
1059	MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. <i>Pharmacological Research</i> , 2020, 155, 104695.	3.1	29
1060	Wnt Signaling Cascade in Dendritic Cells and Regulation of Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 122.	2.2	33
1061	The challenge and prospect of mRNA therapeutics landscape. <i>Biotechnology Advances</i> , 2020, 40, 107534.	6.0	221
1062	Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. <i>Frontiers in Oncology</i> , 2019, 9, 1519.	1.3	61
1063	Herpes Simplex Virus Type-2 Paralyzes the Function of Monocyte-Derived Dendritic Cells. <i>Viruses</i> , 2020, 12, 112.	1.5	15
1064	Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. <i>Biomaterials</i> , 2020, 235, 119795.	5.7	65

#	ARTICLE	IF	CITATIONS
1065	Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. <i>Cancers</i> , 2020, 12, 287.	1.7	131
1066	The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function. <i>Journal of Cancer</i> , 2020, 11, 769-775.	1.2	24
1067	A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. <i>Nature Biomedical Engineering</i> , 2020, 4, 40-51.	11.6	83
1068	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. <i>Pharmaceutics</i> , 2020, 12, 92.	2.0	46
1069	Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. <i>British Journal of Cancer</i> , 2020, 122, 1005-1013.	2.9	52
1070	Toll-like Receptors from the Perspective of Cancer Treatment. <i>Cancers</i> , 2020, 12, 297.	1.7	60
1071	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready to Improve Clinical Outcome?. <i>Cancers</i> , 2020, 12, 299.	1.7	2
1072	Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3157-3166.	3.3	67
1073	Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer. <i>BMC Cancer</i> , 2020, 20, 357.	1.1	9
1074	Biomaterials for cancer immunotherapy. , 2020, , 499-526.		5
1075	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. <i>International Immunopharmacology</i> , 2020, 83, 106446.	1.7	30
1076	Dendritic cell therapy in cancer treatment; the state-of-the-art. <i>Life Sciences</i> , 2020, 254, 117580.	2.0	91
1077	Characterization of a Novel Murine Colon Carcinoma Subline with High-Metastatic Activity Established by In Vivo Selection Method. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2829.	1.8	3
1078	Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death. <i>Small</i> , 2020, 16, e2000214.	5.2	73
1079	Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial. <i>Journal of Translational Medicine</i> , 2020, 18, 176.	1.8	15
1080	TNF- $\alpha$ inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. <i>PLoS ONE</i> , 2020, 15, e0231499.	1.1	9
1081	Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. <i>Cancer Gene Therapy</i> , 2021, 28, 5-17.	2.2	444
1082	Current updates and future perspectives on the management of renal cell carcinoma. <i>Life Sciences</i> , 2021, 264, 118632.	2.0	48

#	ARTICLE	IF	CITATIONS
1083	Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 107-121.	2.0	7
1084	Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. <i>Genetic Epidemiology</i> , 2021, 45, 99-114.	0.6	7
1085	Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1451-1464.	2.0	23
1086	Bio-membrane adhesive poly(choline phosphate l-glutamate)-based nanoparticles as vaccine delivery systems for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2021, 417, 127970.	6.6	7
1087	Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 729-739.	3.2	5
1088	Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and <scp>P5</scp> peptide: A novel vaccine for breast cancer. <i>Biotechnology Progress</i> , 2021, 37, e3095.	1.3	12
1089	Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1075-1088.	2.0	18
1090	Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 218-230.	1.1	6
1091	Immunohistochemical analysis of the aggregation of CD1a-positive dendritic cells in resected specimens and its association with surgical outcomes for patients with gallbladder cancer. <i>Translational Oncology</i> , 2021, 14, 100923.	1.7	6
1092	Tumor cell-derived autophagosomes (DRibbles)-activated B cells induce specific na~ve CD8+ T cell response and exhibit antitumor effect. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 463-474.	2.0	5
1093	Nanoparticles in cancer immunotherapies: An innovative strategy. <i>Biotechnology Progress</i> , 2021, 37, e3070.	1.3	14
1094	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
1095	Nano-immunotherapy: Overcoming tumour immune evasion. <i>Seminars in Cancer Biology</i> , 2021, 69, 238-248.	4.3	47
1096	<i>In situ</i> injection of dual-delivery PEG based MMP-2 sensitive hydrogels for enhanced tumor penetration and chemo-immune combination therapy. <i>Nanoscale</i> , 2021, 13, 9577-9589.	2.8	35
1097	Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?. <i>Theranostics</i> , 2021, 11, 7471-7487.	4.6	26
1098	Interactions between Biomedical Micro~Nano~Motors and the Immune Molecules, Immune Cells, and the Immune System: Challenges and Opportunities. <i>Advanced Healthcare Materials</i> , 2021, 10, e2001788.	3.9	32
1099	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
1100	Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer. <i>OncImmunity</i> , 2021, 10, 1875638.	2.1	27



#	ARTICLE	IF	CITATIONS
1101	Multiple Myeloma and Dendritic Cell Vaccines. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 370-377.	0.1	0
1102	Methotrexate enhances antigen presentation and maturation of tumour antigen-loaded dendritic cells through NLRP3 inflammasome activation: a strategy for dendritic cell-based cancer vaccine. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098705.	1.4	8
1103	Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing. <i>Science Advances</i> , 2021, 7, .	4.7	88
1104	Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 42-88.	0.1	0
1105	ATP stabilised and sensitised calcium phosphate nanoparticles as effective adjuvants for a DNA vaccine against cancer. <i>Journal of Materials Chemistry B</i> , 2021, 9, 7435-7446.	2.9	13
1106	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. <i>Bioengineered</i> , 2021, 12, 1642-1662.	1.4	6
1107	A near-infrared light-excitable immunomodulating nano-photosensitizer for effective photoimmunotherapy. <i>Biomaterials Science</i> , 2021, 9, 4191-4198.	2.6	8
1108	AURKA and FAM83A are prognostic biomarkers and correlated with Tumor-infiltrating Lymphocytes in smoking related Lung Adenocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 1742-1754.	1.2	8
1109	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 33-54.	0.8	3
1110	Prediction of Response in Head and Neck Tumor: Focus on Main Hot Topics in Research. <i>Frontiers in Oncology</i> , 2020, 10, 604965.	1.3	6
1111	Dendritic Cell-Based Immunotherapy in Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 620374.	2.2	31
1112	In situ poly I:C released from living cell drug nanocarriers for macrophage-mediated antitumor immunotherapy. <i>Biomaterials</i> , 2021, 269, 120670.	5.7	24
1113	Pathogenetic Features and Current Management of Glioblastoma. <i>Cancers</i> , 2021, 13, 856.	1.7	29
1114	Robust Nanovaccine Based on Polydopamine-Coated Mesoporous Silica Nanoparticles for Effective Photothermal-Immunotherapy Against Melanoma. <i>Advanced Functional Materials</i> , 2021, 31, 2010637.	7.8	65
1115	Vaccination as Immunotherapy in Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 433-443.	0.8	8
1116	Bacteria-Based Cancer Immunotherapy. <i>Advanced Science</i> , 2021, 8, 2003572.	5.6	115
1117	Noninvasively immunogenic sonodynamic therapy with manganese protoporphyrin liposomes against triple-negative breast cancer. <i>Biomaterials</i> , 2021, 269, 120639.	5.7	74
1118	Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 98.	1.8	46

#	ARTICLE	IF	CITATIONS
1119	Antitumour metastasis and the antiangiogenic and antitumour effects of a Eimeria stiedae soluble protein. <i>Parasite Immunology</i> , 2021, 43, e12825.	0.7	3
1120	Prognostic significance of chemokines CCL11 and CCL5 modulated by low-density lipoprotein cholesterol in colon cancer patients with normal body mass index. <i>Annals of Translational Medicine</i> , 2021, 9, 202-202.	0.7	10
1121	Biomimetic Nanoemulsion for Synergistic Photodynamicâ€Immuno-therapy Against Hypoxic Breast Tumor. <i>Angewandte Chemie</i> , 2021, 133, 10742-10748.	1.6	13
1122	Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response. <i>Pathogens</i> , 2021, 10, 275.	1.2	3
1123	Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and Its Role in the Therapy of Various Types of Cancer through the Modulation of Various Cell Signaling Pathways. <i>Molecules</i> , 2021, 26, 1315.	1.7	73
1124	Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy. <i>Biomaterials</i> , 2021, 270, 120690.	5.7	21
1125	Biomimetic Nanoemulsion for Synergistic Photodynamicâ€Immuno-therapy Against Hypoxic Breast Tumor. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10647-10653.	7.2	96
1126	Development of a Cancer Vaccine Using In Vivo Clickâ€Chemistryâ€Mediated Active Lymph Node Accumulation for Improved Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2006007.	11.1	70
1127	Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	9
1128	Mannose-Functionalized Biodegradable Nanoparticles Efficiently Deliver DNA Vaccine and Promote Anti-tumor Immunity. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 14015-14027.	4.0	35
1129	cGASâ€STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells. <i>Scientific Reports</i> , 2021, 11, 7243.	1.6	36
1130	Dendritic Cells Are Associated with Prognosis and Survival in Breast Cancer. <i>Diagnostics</i> , 2021, 11, 702.	1.3	22
1131	Modeling Dendritic Cell Pulsed Immunotherapy for Mice with Melanomaâ€Protocols for Success and Recurrence. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 3199.	1.3	0
1132	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. <i>Cells</i> , 2021, 10, 927.	1.8	8
1133	NEIL3 may act as a potential prognostic biomarker for lung adenocarcinoma. <i>Cancer Cell International</i> , 2021, 21, 228.	1.8	14
1135	Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?. <i>Acta Biomaterialia</i> , 2021, 125, 1-28.	4.1	36
1136	The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 656908.	2.2	67
1137	Protein-Based Nanomedicine for Therapeutic Benefits of Cancer. <i>ACS Nano</i> , 2021, 15, 8001-8038.	7.3	59

#	ARTICLE	IF	CITATIONS
1138	A combination of ssGSEA and mass cytometry identifies immune microenvironment in muscle-invasive bladder cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23754.	0.9	9
1139	Innate and adaptive immune responses toward nanomedicines. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 852-870.	5.7	26
1140	An Ultra-Stable, Oxygen-Supply Nanoprobe Emitting in Near-Infrared Window to Guide and Enhance Radiotherapy by Promoting Anti-Tumor Immunity. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100090.	3.9	27
1141	Artificial Engineering of Immune Cells for Improved Immunotherapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000081.	1.7	4
1142	Laser-Assisted epicutaneous immunization to target human skin dendritic cells. <i>Experimental Dermatology</i> , 2021, 30, 1279-1289.	1.4	6
1143	Preclinical models and technologies to advance nanovaccine development. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 148-182.	6.6	18
1144	Shaping of T Cell Functions by Trogocytosis. <i>Cells</i> , 2021, 10, 1155.	1.8	17
1145	Induced pluripotent stem cell-derived, genetically engineered myeloid cells as unlimited cell source for dendritic cell-related cancer immunotherapy. <i>Journal of Immunology and Regenerative Medicine</i> , 2021, 12, 100042.	0.2	0
1146	In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. , 2021, 9, e002432.		21
1147	Novel cell-based therapies in inflammatory bowel diseases: the established concept, promising results. <i>Human Cell</i> , 2021, 34, 1289-1300.	1.2	18
1148	The Crosstalk Between Dendritic Cells, Cytokine-Induced Killer Cells And Cancer Cells From The Perspective Of Combination Therapy. <i>Russian Open Medical Journal</i> , 2021, 10, .	0.1	0
1149	The Host-Defense-Peptide-Mimicking Synthetic Polypeptides Effectively Enhance Antitumor Immunity through Promoting Immunogenic Tumor Cell Death. <i>Macromolecular Bioscience</i> , 2021, 21, e2100171.	2.1	6
1150	Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies. <i>Cancers</i> , 2021, 13, 2821.	1.7	26
1151	Emerging nanomaterials for cancer immunotherapy. <i>Exploration of Medicine</i> , 2021, 2, 208-231.	1.5	1
1152	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 690499.	2.2	59
1153	IL-33/ST2 as a potential target for tumor immunotherapy. <i>European Journal of Immunology</i> , 2021, 51, 1943-1955.	1.6	22
1154	Immunotherapy in malignant pleural mesothelioma: a review of literature data. <i>Translational Lung Cancer Research</i> , 2021, 10, 2988-3000.	1.3	11
1155	Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. <i>AAPS Journal</i> , 2021, 23, 90.	2.2	19

#	ARTICLE	IF	CITATIONS
1156	Facile Transformation of Murine and Human Primary Dendritic Cells into Robust and Modular Artificial Antigen-Presenting Systems by Intracellular Hydrogelation. <i>Advanced Materials</i> , 2021, 33, e2101190.	11.1	11
1157	Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis. <i>Life Sciences</i> , 2021, 277, 119505.	2.0	12
1158	Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8035.	1.8	30
1159	Identification and Validation of PIK3CA as a Marker Associated with Prognosis and Immune Infiltration in Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	3
1160	Hydrogel-By-Design: Smart Delivery System for Cancer Immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 723490.	2.0	23
1161	Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8044.	1.8	40
1162	Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 14661.	1.6	19
1163	Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages. <i>Frontiers in Immunology</i> , 2021, 12, 691134.	2.2	59
1164	Overview of implantable and injectable biomaterials in immunotherapy. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 16, 195-201.	0.1	0
1165	Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. , 2021, 9, e003132.		17
1166	T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8679.	1.8	3
1167	Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2021, 133, 257-267.	4.1	20
1168	Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets. <i>Biomolecules</i> , 2021, 11, 1232.	1.8	20
1169	Tumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5395-5409.	3.3	25
1170	How Human Herpesviruses Subvert Dendritic Cell Biology and Function. , 0, , .		0
1171	A Polysaccharide From the Whole Plant of <i>Plantago asiatica</i> L. Enhances the Antitumor Activity of Dendritic Cell-Based Immunotherapy Against Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 678865.	1.6	10
1172	Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment. <i>ACS Nano</i> , 2021, 15, 12567-12603.	7.3	112
1173	Analysis of Bulk RNA Sequencing Data Reveals Novel Transcription Factors Associated With Immune Infiltration Among Multiple Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 644350.	2.2	6

#	ARTICLE	IF	CITATIONS
1175	Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101225.	6.2	45
1176	Multistage Cooperative Nanodrug Combined with PD-1 for Enhancing Antitumor Chemoimmunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2101199.	3.9	14
1177	Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-1 Expression for Circumventing Immune Resistance of Cancer. <i>Advanced Materials</i> , 2021, 33, e2102668.	11.1	36
1178	Tumor-reactive T cells are licensed by dendritic cells located in spatially different tissues: implications for dendritic cell vaccines. <i>Oncotarget</i> , 2021, 12, 1631-1633.	0.8	0
1179	A Mannosylated, PEGylated Albumin as a Drug Delivery System for the Treatment of Cancer Stroma Cells. <i>Advanced Functional Materials</i> , 2021, 31, 2104136.	7.8	11
1180	CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2021, , 1-12.	0.6	6
1181	Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. <i>Nature Communications</i> , 2021, 12, 5291.	5.8	98
1182	Proteomics special issue: Precision immunology and oncology. <i>Proteomics</i> , 2021, 21, 2000159.	1.3	0
1183	Lymph-Node-Targeted Cholesterolized TLR7 Agonist Liposomes Provoke a Safe and Durable Antitumor Response. <i>Nano Letters</i> , 2021, 21, 7960-7969.	4.5	22
1184	A Redox-Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2101222.	3.9	23
1185	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2
1186	Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10268.	1.8	11
1187	Dynamics of immunotherapy antitumor models with impulsive control strategy. <i>Mathematical Methods in the Applied Sciences</i> , 2022, 45, 483-499.	1.2	3
1188	Immunomodulatory Effect of Irreversible Electroporation Alone and Its Cooperating With Immunotherapy in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 712042.	1.3	15
1189	Crosstalk between estrogen, dendritic cells, and SARS-CoV-2 infection. <i>Reviews in Medical Virology</i> , 2022, 32, e2290.	3.9	10
1190	Mathematical Model for Delayed Responses in Immune Checkpoint Blockades. <i>Bulletin of Mathematical Biology</i> , 2021, 83, 106.	0.9	1
1191	Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111798.	2.5	33
1192	Immune Cycle-Based Strategies for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2107540.	7.8	24

#	ARTICLE	IF	CITATIONS
1193	Nanovaccines silencing IL-10 production at priming phase for boosting immune responses to melanoma. <i>Journal of Controlled Release</i> , 2021, 338, 211-223.	4.8	8
1194	Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). <i>Medicine (United States)</i> , 2021, 100, e27332.	0.4	1
1195	A stromal and immune cell infiltration-based score model predicts prognosis and chemotherapy effect in colorectal cancer. <i>International Immunopharmacology</i> , 2021, 99, 107940.	1.7	4
1196	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	3.5	26
1197	Emerging trends of receptor-mediated tumor targeting peptides: A review with perspective from molecular imaging modalities. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113538.	2.6	16
1198	A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. <i>Chemical Engineering Journal</i> , 2021, 422, 130111.	6.6	20
1199	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48
1200	Personalized cancer immunotherapy. , 2022, , 399-426.		0
1201	Tumor-on-a-chip devices for cancer immunotherapy. , 2022, , 155-195.		1
1202	Heat shock protein vaccines in glioblastoma. , 2022, , 39-53.		0
1203	Stromal modulation strategies to improve immunotherapy response in cancer. , 2022, , 241-291.		0
1204	Polymeric scaffolds for antitumor immune cell priming. , 2022, , 63-95.		2
1205	Application of cancer stem cells in improving therapeutics. , 2021, , 307-339.		0
1206	Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 433.	1.7	22
1207	Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses. <i>Life</i> , 2021, 11, 69.	1.1	66
1208	Cancer Immunotherapy. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 1-41.	0.1	0
1209	Self-assembling, self-adjuvanting and fully synthetic peptide nanovaccine for cancer immunotherapy. <i>Smart Materials in Medicine</i> , 2021, 2, 237-249.	3.7	14
1210	The antiviral potential of algal-derived macromolecules. <i>Current Research in Biotechnology</i> , 2021, 3, 120-134.	1.9	19

#	ARTICLE	IF	CITATIONS
1211	Lipid Metabolism and Tumor Antigen Presentation. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1316, 169-189.	0.8	4
1212	Antigen Delivery to DEC205 <sup>+</sup> Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites. <i>International Journal of Biological Sciences</i> , 2021, 17, 2944-2956.	2.6	11
1213	Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy. <i>ACS Omega</i> , 2021, 6, 3991-3998.	1.6	7
1214	Two-dimensional layered double hydroxide nanoadjuvant: recent progress and future direction. <i>Nanoscale</i> , 2021, 13, 7533-7549.	2.8	48
1215	Nutlin-3a and Cytokine Co-loaded Spermine-Modified Acetalated Dextran Nanoparticles for Cancer Chemotherapy. <i>Advanced Functional Materials</i> , 2017, 27, 1703303.	7.8	61
1216	Pulsing Dendritic Cells with Whole Tumor Cell Lysates. <i>Methods in Molecular Biology</i> , 2014, 1139, 27-31.	0.4	20
1217	A Structured Population Model of Competition Between Cancer Cells and T Cells Under Immunotherapy. <i>Springer Proceedings in Mathematics and Statistics</i> , 2014, , 47-58.	0.1	4
1218	Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine. <i>Methods in Molecular Biology</i> , 2016, 1467, 221-232.	0.4	3
1219	Spinal Cord Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1226, 97-109.	0.8	7
1220	Tenascin-C Function in Glioma: Immunomodulation and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1272, 149-172.	0.8	23
1221	Immunology in Plasma Cancer Treatment. <i>Springer Series on Atomic, Optical, and Plasma Physics</i> , 2020, , 209-222.	0.1	2
1222	Role of Innate Immunity in Cancers and Antitumor Response. , 2015, , 29-46.		1
1223	Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger. <i>Biomaterials</i> , 2020, 252, 120114.	5.7	58
1224	In vivo dynamic cell tracking with long-wavelength excitable and near-infrared fluorescent polymer dots. <i>Biomaterials</i> , 2020, 254, 120139.	5.7	30
1225	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. <i>Cell Reports</i> , 2020, 30, 1027-1038.e4.	2.9	29
1226	Target controllability with minimal mediators in complex biological networks. <i>Genomics</i> , 2020, 112, 4938-4944.	1.3	6
1227	Engineering anti-cancer nanovaccine based on antigen cross-presentation. <i>Bioscience Reports</i> , 2019, 39, .	1.1	47
1230	Vaccine-Elicited CD8 <sup>+</sup> T Cells Cure Mesothelioma by Overcoming Tumor-Induced Immunosuppressive Environment. <i>Cancer Research</i> , 2014, 74, 6010-6021.	0.4	32



#	ARTICLE	IF	CITATIONS
1231	Gut microbiota modulates adoptive cell therapy via CD8 <sup>+</sup> dendritic cells and IL-12. JCI Insight, 2018, 3, .	2.3	111
1232	Efficacy of intracellular immune checkpoint-silenced DC vaccine. JCI Insight, 2018, 3, .	2.3	29
1233	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. Journal of Clinical Investigation, 2020, 130, 774-788.	3.9	47
1234	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. Journal of Clinical Investigation, 2013, 123, 3135-3145.	3.9	55
1235	Hypoxia-inducible factors: a central link between inflammation and cancer. Journal of Clinical Investigation, 2016, 126, 3689-3698.	3.9	144
1236	Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 72-75.	1.6	11
1237	Interleukin-15-Induced CD56 <sup>+</sup> Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PLoS ONE, 2012, 7, e51851.	1.1	48
1238	IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation. PLoS ONE, 2013, 8, e70237.	1.1	31
1239	A Novel and Effective Cancer Immunotherapy Mouse Model Using Antigen-Specific B Cells Selected In Vitro. PLoS ONE, 2014, 9, e92732.	1.1	16
1240	Efficiency of Dendritic Cell Vaccination against B16 Melanoma Depends on the Immunization Route. PLoS ONE, 2014, 9, e105266.	1.1	18
1241	Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis. PLoS ONE, 2014, 9, e107173.	1.1	37
1242	MicroRNA-22 Impairs Anti-Tumor Ability of Dendritic Cells by Targeting p38. PLoS ONE, 2015, 10, e0121510.	1.1	35
1243	Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma. PLoS ONE, 2015, 10, e0136911.	1.1	27
1244	Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin. PLoS ONE, 2017, 12, e0180333.	1.1	15
1245	Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. PLoS ONE, 2018, 13, e0192449.	1.1	48
1246	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. PLoS ONE, 2020, 15, e0239369.	1.1	14
1247	Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells. Cellular and Molecular Biology, 2018, 64, 102.	0.3	2
1248	Recent development and applications of nanomaterials for cancer immunotherapy. Nanotechnology Reviews, 2020, 9, 367-384.	2.6	26

#	ARTICLE	IF	CITATIONS
1249	A Systematic Overview of Cancer Immunotherapy: An Emerging Therapy. <i>Pharmacy &amp; Pharmacology International Journal</i> , 2017, 5, .	0.1	8
1250	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. <i>Radiation Research</i> , 2020, 194, 688-697.	0.7	29
1251	Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells. <i>Oncotarget</i> , 2016, 7, 48860-48869.	0.8	18
1252	Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2/STAT3 pathway. <i>Oncotarget</i> , 2016, 7, 63204-63214.	0.8	15
1253	Laminarin promotes anti-cancer immunity by the maturation of dendritic cells. <i>Oncotarget</i> , 2017, 8, 38554-38567.	0.8	45
1254	Tumor-specific hepatic stellate cells (tHSCs) induces DlgR2 expression in dendritic cells to inhibit T cells. <i>Oncotarget</i> , 2017, 8, 55084-55093.	0.8	7
1255	A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. <i>Oncotarget</i> , 2017, 8, 90488-90495.	0.8	13
1256	Lipopolysaccharide-coated CuS nanoparticles promoted anti-cancer and anti-metastatic effect by immuno-photothermal therapy. <i>Oncotarget</i> , 2017, 8, 105584-105595.	0.8	24
1257	Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 17135-17146.	0.8	52
1258	From kinetics and cellular cooperations to cancer immunotherapies. <i>Oncotarget</i> , 2016, 7, 44779-44789.	0.8	3
1259	Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities. <i>Cancer Biology and Medicine</i> , 2019, 16, 714-728.	1.4	20
1260	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
1261	Dendritic cell-derived exosomes for cancer immunotherapy: hope and challenges. <i>Annals of Translational Medicine</i> , 2017, 5, 221-221.	0.7	56
1262	Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2016, 28, 452-460.	0.7	13
1263	Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy. <i>Current Drug Metabolism</i> , 2020, 21, 579-598.	0.7	11
1264	Exosome as a Natural Gene Delivery Vector for Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2020, 20, 821-830.	0.8	15
1265	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 291-313.	1.0	2
1266	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2158-2175.	1.0	4

#	ARTICLE	IF	CITATIONS
1267	Phage Display Technology and its Applications in Cancer Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 229-235.	0.9	11
1268	Recent Advances in Novel Antibacterial Development. , 2016, , 3-61.		4
1269	In Situ-Induced Multivalent Anticancer Drug Clusters in Cancer Cells for Enhancing Drug Efficacy. <i>CCS Chemistry</i> , 0, , 97-105.	4.6	48
1270	Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells. <i>Acta Naturae</i> , 2016, 8, 17-30.	1.7	18
1271	Acidosis-Induced TGF- $\beta$ 2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response. <i>Cancers</i> , 2020, 12, 1284.	1.7	25
1272	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	1.8	57
1273	Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 12713.	1.4	30
1274	ADOPTIVE CELL THERAPY: CURRENT ADVANCES. <i>South Russian Journal of Cancer</i> , 2020, 1, 43-59.	0.1	5
1275	Multifaceted Actions of Succinate as a Signaling Transmitter Vary with Its Cellular Locations. <i>Endocrinology and Metabolism</i> , 2020, 35, 36.	1.3	24
1276	LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 849-856.	0.2	6
1277	Interaction between circulating cancer cells and platelets: clinical implication. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 450-60.	0.7	67
1278	Immunomodulatory effects of transforming growth factor- $\beta$ 2 in the liver. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 386-406.	0.7	46
1279	Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy. <i>Immune Network</i> , 2019, 19, e23.	1.6	60
1280	Tumour Vaccines, Monoclonals, Proteins or Whole Cell Therapies. <i>Journal of Vaccines &amp; Vaccination</i> , 2013, , .	0.3	1
1281	HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy. <i>World Journal of Vaccines</i> , 2015, 05, 106-128.	0.8	4
1282	Utilizing the nanosecond pulse technique to improve antigen intracellular delivery and presentation to treat tongue squamous cell carcinoma. <i>Medicina Oral, Patología Oral Y Cirugía Bucal</i> , 2018, 23, 0-0.	0.7	3
1283	Vascular endothelia growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 76-77.	0.3	15
1284	<i>Mycobacterium abscessus</i> $\alpha$ -alanine dipeptidase induces the maturation of dendritic cells and promotes Th1-biased immunity. <i>BMB Reports</i> , 2016, 49, 554-559.	1.1	6

#	ARTICLE	IF	CITATIONS
1285	Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes. <i>BiolImpacts</i> , 2012, 2, 127-43.	0.7	18
1286	Immunotherapeutic Effects of Dendritic Cells Pulsed with a Coden-optimized HPV 16 E6 and E7 Fusion Gene in Vivo and in Vitro. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3843-3847.	0.5	6
1287	Near-infrared photoactivatable control of Ca <sup>2+</sup> signaling and optogenetic immunomodulation. <i>ELife</i> , 2015, 4, .	2.8	197
1288	Personalized gel-droplet monocyte vaccines for cancer immunotherapy. <i>Lab on A Chip</i> , 2021, 21, 4414-4426.	3.1	8
1289	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. <i>Journal of Personalized Medicine</i> , 2021, 11, 1031.	1.1	18
1290	Prophylactic dendritic cell vaccination in antitumor immune response and tumor growth in a breast cancer mouse model. <i>Research, Society and Development</i> , 2021, 10, e100101320905.	0.0	0
1291	Mycobacterium tuberculosis Rv3628 is an effective adjuvant via activation of dendritic cells for cancer immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 288-302.	2.0	5
1292	A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase. <i>Biomaterials</i> , 2021, 279, 121180.	5.7	27
1293	Immunotherapeutic Advances for NSCLC. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 399-417.	3.0	9
1294	Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 746621.	2.2	4
1295	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
1297	Dendritic Cells. , 2013, , 1-11.		0
1298	Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets. , 2013, , 431-455.		0
1299	Tumor Immunotherapy by Utilizing a Double-Edged Sword, Chemokines. , 2013, , 97-118.		0
1300	Lung Cancer Immunotherapy: Programmatic Development, Progress, and Perspectives. , 2013, , 385-396.		0
1301	Cancer Gene Therapy: Targeted Genomedicines. , 0, , .		0
1302	Innate and Adaptive Immune Responses to Cancer. , 2014, , 81-121.		1
1303	Immune Cells Within the Tumor Microenvironment. , 2014, , 1-23.		2

#	ARTICLE	IF	CITATIONS
1304	Cancer Vaccines: Fundamentals and Strategies. <i>Advances in Delivery Science and Technology</i> , 2014, , 163-185.	0.4	0
1305	Ex Vivo Loading of Autologous Dendritic Cells with Tumor Antigens. <i>Methods in Molecular Biology</i> , 2014, 1139, 41-44.	0.4	2
1306	Expression of tolerogenic potential-presenting markers on clinical-grade therapeutic dendritic cell-based cancer vaccines. <i>Acta Medica Lituanica</i> , 2014, 20, 161-173.	0.2	0
1307	Cancer Immunotherapy: How to Optimize Immunotherapy. <i>MOJ Immunology</i> , 2014, 1, .	11.0	0
1309	<i>Frontiers in Cancer Immunotherapy</i> . , 2015, , 1-22.		1
1310	DC Maturation: A Brief Comparison between Three Different Processes. <i>Journal of Cancer Therapy</i> , 2015, 06, 871-880.	0.1	1
1311	Regulation of Anti-Tumor Immune Responses. , 2015, , 143-158.		0
1312	InCVAX as a Novel In Situ Autologous Cancer Vaccine. , 2015, , .		0
1313	Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 31-58.	0.1	0
1314	<i>Dendritic Cells</i> . , 2015, , 1-11.		0
1316	Anti-TIM-3 Antibody Prevents Lymphocyte Apoptosis and Enhances Dendritic Cell Cancer Therapy. <i>The Showa University Journal of Medical Sciences</i> , 2015, 27, 1-9.	0.1	0
1319	<i>Immunopharmacologic Approaches to Treat Cancer</i> . , 2016, , 397-425.		0
1320	<i>Dendritic Cells</i> . , 2016, , 439-448.		0
1321	<i>Aspects of Autophagy in Inflammatory Bowel Disease</i> . , 2016, , 235-265.		0
1322	<i>Cancer Vaccines</i> . , 2016, , 295-333.		0
1323	<i>Promising Immunotherapeutic Approaches in Clinical Trials</i> . , 2016, , 351-416.		1
1324	<i>Dendritic Cells</i> . , 2016, , 143-166.		0
1325	<i>Dendritic Cells in Colorectal Cancer and a Potential for their Use in Therapeutic Approaches</i> . <i>Current Pharmaceutical Design</i> , 2016, 22, 2431-2438.	0.9	8

#	ARTICLE	IF	CITATIONS
1327	Clinical Trial Analysis of Different Stages of HBV Patients Treated with Human CIK Cells. <i>Nano Biomedicine and Engineering</i> , 2016, 8, .	0.3	0
1328	Chapter 9 Tracking of Dendritic Cells. , 2016, , 243-282.		0
1329	The Future in Ovarian Cancer: Advances in Immunotherapies. , 2017, , 143-168.		0
1330	Phenotypical and functional properties of generated dendritic cells in lung cancer patients. <i>Cell and Organ Transplantation</i> , 2016, 4, 162-166.	0.2	2
1331	The Prospect and Issue of Anticancer Therapy in Head and Neck Cancer. <i>Journal of Clinical Otolaryngology</i> , 2016, 27, 239-245.	0.1	0
1332	Nutrition and its Important Role in Maintaining an Adequate Immunity during Chemotherapy. <i>Gynecology &amp; Obstetrics (Sunnyvale, Calif )</i> , 0, s5, .	0.1	0
1333	Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. , 2017, , 225-241.		0
1334	Bacterial Pore-Forming Toxin in Macromolecule Delivery: Lessons Learned from Listeriolysin O. <i>Toxinology</i> , 2017, , 1-13.	0.2	0
1335	Exosomes: Navigating a New Route in Pancreatic Cancer. <i>Journal of Biomolecular Research &amp; Therapeutics</i> , 2017, 06, .	0.2	0
1336	Phenotypic features of generated dendritic cells in patients with pancreatic cancer immunotherapy. <i>ScienceRise: Medical Science</i> , 2017, .	0.0	0
1337	The Effect of Granulocyte Macrophage-Colony Stimulating Factor upon the Induction of Peripheral Blood Dendritic and Natural Killer Cells When Given Simultaneously with a Slow Continuous Doxorubicin Infusion. <i>Journal of Cancer Therapy</i> , 2017, 08, 637-644.	0.1	0
1338	Synergetic immunotherapies and current molecular targets in oral cancer treatment. <i>Journal of Dr NTR University of Health Sciences</i> , 2017, 6, 73.	0.0	0
1339	Atherosclerosis and Helminths Infection. , 0, , .		0
1340	Application of dendritic cell based vaccination in adjuvant treatment of patients with pancreatic cancer. <i>ScienceRise: Medical Science</i> , 2017, .	0.0	0
1341	DlgR2 knockdown boosts dendritic cell activity and inhibits hepatocellular carcinoma tumor <i>in-situ</i> growth. <i>Oncotarget</i> , 2017, 8, 54993-55002.	0.8	2
1342	Designing a Chimeric Vaccine Against Colorectal Cancer. <i>International Journal of Cancer Management</i> , 2017, 10, .	0.2	0
1343	Road to Cancer Cure€“So Near and Yet So Far. <i>Journal of Medical Academics</i> , 2018, 1, 94-101.	0.1	0
1345	Bacterial Pore-Forming Toxin in Macromolecule Delivery: Lessons Learned from Listeriolysin O. <i>Toxinology</i> , 2018, , 317-328.	0.2	0

#	ARTICLE	IF	CITATIONS
1347	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
1348	Possible Involvement of Cancer Producing Thymic Stromal Lymphopoietin as an Initiator of Papuloerythroderma of Ofuji. Annals of Dermatology, 2019, 31, S56.	0.3	1
1349	Principles of Immuno-Oncology. , 2019, , 113-120.		0
1350	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
1351	Cancer Therapy. , 2019, , 7-76.		0
1352	Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies. European Oncology and Haematology, 2019, 15, 22.	0.0	1
1353	Precision oncology: myth or reality?. Bulletin of Russian State Medical University, 2019, , 5-14.	0.3	0
1354	DESIGNING A VACCINE FOR CANCER: A LOOK INTO DENDRITIC CELL CANCER VACCINE. Asian Journal of Pharmaceutical and Clinical Research, 0, , 27-31.	0.3	0
1355	In vitro dendritic cell maturation isolated from healthy people and patients with Staphylococcus aureuscaused chronic osteomyelitis. Russian Journal of Infection and Immunity, 2019, 9, 87-94.	0.2	0
1356	Nrf2 activation mediates tumor-specific hepatic stellate cells-induced DlgR2 expression in dendritic cells. Aging, 2019, 11, 11565-11575.	1.4	2
1357	Optimized Dose of Dendritic Cell-based Vaccination in Experimental Model of Tumor Using Artificial Neural Network. Iranian Journal of Allergy, Asthma and Immunology, 2020, 19, 172-182.	0.3	1
1358	Tumour-infiltrating Langerhans cells in non-melanoma skin cancer, a clinical and immunohistochemical study. Ecancermedalscience, 2020, 14, 1045.	0.6	5
1359	Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. Academic Radiology, 2020, 28, e147-e154.	1.3	8
1360	Targeting cluster of differentiation 1/247 improves the efficacy of anti-cytotoxic T lymphocyte associated protein 1/24 treatment via antigen presentation enhancement in pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine, 2020, 20, 3301-3309.	0.8	3
1361	Well-defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity. Advanced Healthcare Materials, 2022, 11, e2101651.	3.9	24
1362	Photosynthetic microorganisms coupled photodynamic therapy for enhanced antitumor immune effect. Bioactive Materials, 2022, 12, 97-106.	8.6	23
1363	Biomimetic nanomedicine toward personalized disease theranostics. Nano Research, 2021, 14, 2491-2511.	5.8	17
1364	Introduction to cancer and treatment approaches. , 2022, , 1-27.		3



#	ARTICLE	IF	CITATIONS
1365	Wnt signaling pathway in cancer immunotherapy. <i>Cancer Letters</i> , 2022, 525, 84-96.	3.2	60
1366	The Role of Human Dendritic Cell Subsets in Antitumor Immunity. <i>Advances in Clinical Medicine</i> , 2020, 10, 232-238.	0.0	0
1367	Role of Innate Immunity in Cancers and Antitumor Response. , 2020, , 11-28.		0
1368	An Intellectual History of Multilevel Selection: Reformulation and Resuscitation. , 2020, , 41-70.		0
1369	Reprogramming immunosuppressive tumour-associated dendritic cells with GADD45 <sup>12</sup> inhibitors. <i>Clinical Medicine</i> , 2020, 20, s116-s116.	0.8	0
1370	Dendritic Cellâ€“Targeted Therapies to Treat Neurological Disorders. <i>Molecular Neurobiology</i> , 2022, 59, 603-619.	1.9	3
1371	Equipping Cancer Cell Membrane Vesicles with Functional DNA as a Targeted Vaccine for Cancer Immunotherapy. <i>Nano Letters</i> , 2021, 21, 9410-9418.	4.5	39
1372	Inhalable Polymeric Micro and Nano-immunoadjuvants for Developing Therapeutic Vaccines in the Treatment of Non-small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2022, 28, 395-409.	0.9	1
1373	Frontiers in Cancer Immunotherapy. , 2021, , 1-23.		0
1375	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. <i>ChemistrySelect</i> , 2022, 7, 833-866.	0.7	0
1376	Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. <i>American Journal of Clinical and Experimental Immunology</i> , 2013, 2, 195-207.	0.2	38
1377	Optimizing dendritic cell-based approaches for cancer immunotherapy. <i>Yale Journal of Biology and Medicine</i> , 2014, 87, 491-518.	0.2	40
1378	Wnt signaling in dendritic cells: its role in regulation of immunity and tolerance. <i>Discovery Medicine</i> , 2015, 19, 303-10.	0.5	85
1379	Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells. <i>Acta Naturae</i> , 2016, 8, 17-30.	1.7	10
1380	The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies. <i>Journal of Immunology Research and Therapy</i> , 2017, 2, 68-79.	1.0	20
1382	Mouse dendritic cell migration in abdominal lymph nodes by intraperitoneal administration. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 2859-2867.	0.0	8
1383	Exosomes in cancer therapy: a novel experimental strategy. <i>American Journal of Cancer Research</i> , 2018, 8, 2165-2175.	1.4	22
1384	Magnetic resonance imaging monitoring therapeutic response to dendritic cell vaccine in murine orthotopic pancreatic cancer models. <i>American Journal of Cancer Research</i> , 2019, 9, 562-573.	1.4	6

#	ARTICLE	IF	CITATIONS
1385	Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 145-159.	0.2	3
1386	Anticancer therapeutics: a brief account on wide refinements. <i>American Journal of Cancer Research</i> , 2020, 10, 3599-3621.	1.4	1
1387	A dendritic cell-like biomimetic nanoparticle enhances T cell activation for breast cancer immunotherapy. <i>Chemical Science</i> , 2021, 13, 105-110.	3.7	9
1388	Bridging micro/nano-platform and airway allergy intervention. <i>Journal of Controlled Release</i> , 2022, 341, 364-382.	4.8	7
1389	Theranostic nanoparticles with disease-specific administration strategies. <i>Nano Today</i> , 2022, 42, 101335.	6.2	54
1390	Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12339.	1.8	23
1391	The prognostic value of TPM1 in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, , .	1.3	11
1392	Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 793-809.	3.2	43
1393	Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174.	1.3	49
1394	Enpp2 Expression by Dendritic Cells Is a Key Regulator in Migration. <i>Biomedicines</i> , 2021, 9, 1727.	1.4	4
1396	Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 389.	4.2	37
1397	Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth. <i>Frontiers in Immunology</i> , 2021, 12, 772555.	2.2	4
1399	A Carrier-Free Photodynamic Nanodrug Enabling Regulation of Dendritic Cells for Boosting Cancer Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1400	Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model. <i>PLoS ONE</i> , 2022, 17, e0262453.	1.1	8
1401	Germline mutations and blood malignancy (Review). <i>Oncology Reports</i> , 2020, 45, 49-57.	1.2	2
1402	Problems of clinical trials of cell therapy effectiveness today. <i>The Siberian Scientific Medical Journal</i> , 2021, 41, 16-32.	0.1	1
1403	Photosensitizer Nanodot Eliciting Immunogenicity for Photo-Immunologic Therapy of Postoperative Methicillin-Resistant <i>Staphylococcus aureus</i> Infection and Secondary Recurrence. <i>Advanced Materials</i> , 2022, 34, e2107300.	11.1	44
1404	A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model. <i>Journal of Nanobiotechnology</i> , 2022, 20, 54.	4.2	4

#	ARTICLE	IF	CITATIONS
1405	Sialic acid blockade in dendritic cells enhances CD8+ T cell responses by facilitating high-avidity interactions. Cellular and Molecular Life Sciences, 2022, 79, 98.	2.4	10
1406	CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model. , 2022, 10, e003809.		17
1407	Cancer therapy, immunotherapy, photothermal therapy. , 2022, , 85-117.		0
1408	Potential of <i>Mycobacterium tuberculosis</i> chorismate mutase (Rv1885c) as a novel TLR4-mediated adjuvant for dendritic cell-based cancer immunotherapy. Oncolmmunology, 2022, 11, 2023340.	2.1	6
1409	Nanozyme-Based Enhanced Cancer Immunotherapy. Tissue Engineering and Regenerative Medicine, 2022, 19, 237-252.	1.6	24
1410	Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling. , 2022, 10, e003827.		14
1411	New Therapeutic Approaches for Conjunctival Melanoma—What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. International Journal of Molecular Sciences, 2022, 23, 1478.	1.8	4
1412	Glioblastoma vaccine tumor therapy research progress. Chinese Neurosurgical Journal, 2022, 8, 2.	0.3	22
1413	Systemic immune responses to irradiated tumours via the transport of antigens to the tumour periphery by injected flagellate bacteria. Nature Biomedical Engineering, 2022, 6, 44-53.	11.6	71
1414	Orchestrated Yolk-Shell Nanohybrids Regulate Macrophage Polarization and Dendritic Cell Maturation for Oncotherapy with Augmented Antitumor Immunity. Advanced Materials, 2022, 34, e2108263.	11.1	53
1415	Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy. Journal of Nanobiotechnology, 2022, 20, 61.	4.2	20
1416	Hybrid in situ-forming injectable hydrogels for local cancer therapy. International Journal of Pharmaceutics, 2022, 616, 121534.	2.6	25
1417	Identification of the Marine Alkaloid Lepadin A as Potential Inducer of Immunogenic Cell Death. Biomolecules, 2022, 12, 246.	1.8	8
1418	Dendritic cell immunotherapy with miR-155 enriched tumor-derived exosome suppressed cancer growth and induced antitumor immune responses in murine model of colorectal cancer induced by CT26 cell line. International Immunopharmacology, 2022, 104, 108493.	1.7	16
1419	Nanovaccines with cell-derived components for cancer immunotherapy. Advanced Drug Delivery Reviews, 2022, 182, 114107.	6.6	41
1420	Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. Journal of Controlled Release, 2022, 343, 379-391.	4.8	12
1421	A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients. Integrative Cancer Therapies, 2022, 21, 153473542210839.	0.8	8
1422	Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. , 2022, , 129-148.		0

#	ARTICLE	IF	CITATIONS
1424	Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 247-268.	2.4	8
1425	Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. <i>Cancers</i> , 2022, 14, 978.	1.7	12
1427	Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. , 2022, 10, e003663.		32
1428	End Group Dye-Labelled Polycarbonate Block Copolymers for Micellar (Immuno-)Drug Delivery. <i>Macromolecular Rapid Communications</i> , 2022, 43, e2200095.	2.0	9
1429	Genetic Engineering of Dendritic Cells Using Partially Zwitterionic Dendrimer-Entrapped Gold Nanoparticles Boosts Efficient Tumor Immunotherapy. <i>Biomacromolecules</i> , 2022, 23, 1326-1336.	2.6	12
1430	Tolerogenic IDO1+CD83 <sup>hi</sup> Langerhans Cells in Sentinel Lymph Nodes of Patients with Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3441.	1.8	5
1431	Integrative analysis of genomic and transcriptomic data of normal, tumour, and co-occurring leukoplakia tissue triads drawn from patients with gingivobuccal oral cancer identifies signatures of tumour initiation and progression. <i>Journal of Pathology</i> , 2022, 257, 593-606.	2.1	13
1432	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
1433	Immunosuppressive properties of human PD-1 <sup>hi</sup> and PDL-1 <sup>hi</sup> and CD80 <sup>hi</sup> dendritic cells from lymph nodes aspirates of lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2469-2483.	2.0	3
1434	Mechanisms of selective monocyte targeting by liposomes functionalized with a cationic, arginine-rich lipopeptide. <i>Acta Biomaterialia</i> , 2022, 144, 96-108.	4.1	7
1435	Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers. <i>Cancers</i> , 2022, 14, 1681.	1.7	64
1436	Precision design of engineered nanomaterials to guide immune systems for disease treatment. <i>Matter</i> , 2022, 5, 1162-1191.	5.0	11
1437	Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1593-1608.	3.3	14
1438	TRAF6-overexpressing dendritic cells loaded with MUC1 peptide enhance anti-tumor activity in B16-MUC1 melanoma-bearing mice. <i>International Immunopharmacology</i> , 2022, 107, 108667.	1.7	2
1439	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. <i>Bioactive Materials</i> , 2022, 16, 107-119.	8.6	24
1440	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
1441	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. <i>Aging</i> , 2021, 13, 25518-25549.	1.4	3
1442	Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity. <i>Methods in Molecular Biology</i> , 2022, 2410, 627-647.	0.4	2

#	ARTICLE	IF	CITATIONS
1443	Immunological responses to adjuvant vaccination with combined CD1c <sup>+</sup> myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>OncImmunology</i> , 2022, 11, .	2.1	14
1444	Immunotherapy against Gliomas. , 0, , .		0
1445	Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2138444.	2.8	0
1446	Fascinating Dendritic Cellsâ€™ Sentinel Cells of the Immune System a Review. <i>Folia Veterinaria</i> , 2021, 65, 12-19.	0.2	0
1447	Amino acid sequence determines the adjuvant potency of a<scp>d</scp>-tetra-peptide hydrogel. <i>Biomaterials Science</i> , 2022, 10, 3092-3098.	2.6	8
1448	Identification of an immune gene-associated prognostic signature in patients with bladder cancer. <i>Cancer Gene Therapy</i> , 2022, 29, 494-504.	2.2	6
1449	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. <i>Nature Nanotechnology</i> , 2022, 17, 531-540.	15.6	125
1501	Antigen-derived peptides engage the ER stress sensor IRE1 $\hat{\pm}$ to curb dendritic cell cross-presentation. <i>Journal of Cell Biology</i> , 2022, 221, .	2.3	17
1502	Immunotherapy in leukaemia. <i>Acta Clinica Belgica</i> , 2012, 67, 399-402.	0.5	3
1503	A TUMOR-IMMUNE MODEL WITH MIXED IMMUNOTHERAPY AND CHEMOTHERAPY: QUALITATIVE ANALYSIS AND OPTIMAL CONTROL. <i>Journal of Biological Systems</i> , 0, , 1-26.	0.5	2
1504	Near-Complete Remission of Glioblastoma in a Patient Treated with an Allogenic Dendritic Cell-Based Vaccine: The Role of Tumor-Specific CD4 <sup>+</sup> T-Cell Cytokine Secretion Pattern in Predicting Response and Recurrence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5396.	1.8	4
1505	The oncogenic role of tubulin alpha-1c chain in human tumours. <i>BMC Cancer</i> , 2022, 22, 498.	1.1	8
1506	Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114308.	6.6	23
1507	Split bullets loaded nanoparticles for amplified immunotherapy. <i>Journal of Controlled Release</i> , 2022, 347, 199-210.	4.8	9
1508	Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. <i>Cancers</i> , 2022, 14, 2438.	1.7	6
1509	A carrier-free photodynamic nanodrug to enable regulation of dendritic cells for boosting cancer immunotherapy. <i>Acta Biomaterialia</i> , 2022, 147, 366-376.	4.1	15
1510	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
1511	Exosome Transportation-Mediated Immunosuppression Relief Via Cascade Amplification for Enhanced Apoptotic Body Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1512	Envelope virus-mimetic nanovaccines by hybridizing bioengineered cell membranes with bacterial vesicles. <i>IScience</i> , 2022, , 104490.	1.9	4
1513	The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1514	Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	19
1515	Phytochemical Engineered Bacterial Outer Membrane Vesicles for Photodynamic Effects Promoted Immunotherapy. <i>Nano Letters</i> , 2022, 22, 4491-4500.	4.5	31
1516	Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1517	Mining database and verification of PIK3CB as a marker predicting prognosis and immune infiltration in renal clear cell carcinoma. <i>Medicine (United States)</i> , 2022, 101, e29254.	0.4	2
1519	Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. <i>Frontiers in Nanotechnology</i> , 0, 4, .	2.4	3
1520	In vivo Protein Interference: Oral Administration of Recombinant Yeast-Mediated Partial Leptin Reduction for Obesity Control. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
1521	Emerging Biomaterials Imaging Antitumor Immune Response. <i>Advanced Materials</i> , 2022, 34, .	11.1	22
1522	Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges. , 0, , .		0
1523	Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1524	Haptoglobin Induces a Specific Proteomic Profile and a Mature-Associated Phenotype on Primary Human Monocyte-Derived Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6882.	1.8	4
1525	Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosaic virus with polydopamine coat. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 44, 102573.	1.7	10
1528	In situ IL-2/IL-12 released from SiO <sub>2</sub> -engineered dendritic cells for synergistic immunotherapy. <i>Nanoscale</i> , 0, , .	2.8	1
1529	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1530	Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7325.	1.8	7
1531	Transient Lymph Node Immune Activation by Hydrolysable Polycarbonate Nanogels. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	11
1532	Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates. <i>Pharmaceutics</i> , 2022, 14, 1358.	2.0	5

#	ARTICLE	IF	CITATIONS
1533	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>OncolImmunology</i> , 2022, 11, .	2.1	54
1534	Immunization With Lipopolysaccharide-Activated Dendritic Cells Generates a Specific CD8+ T Cell Response That Confers Partial Protection Against Infection With <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
1535	Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 583-595.	4.3	10
1536	Acoustic triggered nanobomb for US imaging guided sonodynamic therapy and activating antitumor immunity. <i>Drug Delivery</i> , 2022, 29, 2177-2189.	2.5	6
1537	Antigen self-presenting nanovaccine for cancer immunotherapy. <i>Science Bulletin</i> , 2022, 67, 1611-1613.	4.3	9
1538	Construction of a T7 phage display nanobody library for bio-panning and identification of chicken dendritic cell-specific binding nanobodies. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1539	Mathematical Modeling and Analysis of CD200â€“CD200R in Cancer Treatment. <i>Bulletin of Mathematical Biology</i> , 2022, 84, .	0.9	2
1540	Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1541	Colorectal cancer immunotherapy-Recent progress and future directions. <i>Cancer Letters</i> , 2022, 545, 215816.	3.2	32
1542	Immune-Endocrine Perspectives of Breast Cancer. , 2022, , 22-61.		0
1544	mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 1572.	2.0	20
1545	Evaluation of long antigen exposition dendritic cell therapy (LANEX-DCÂ®) in the adjuvant treatment of pancreatic cancer â€” results of a single center analysis. <i>Archives of Cancer Science and Therapy</i> , 2022, 6, 006-008.	0.0	0
1546	<sc><i>H2AFX</i></sc> might be a prognostic biomarker for hepatocellular carcinoma. <i>Cancer Reports</i> , 2023, 6, .	0.6	2
1547	A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 signaling pathway in HCC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1548	An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis. <i>OncolImmunology</i> , 2022, 11, .	2.1	1
1549	The role of anti-tumor immunity of focused ultrasound for the malignancies: depended on the different ablation categories. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1543-1553.	1.0	3
1550	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 871-898.	2.7	8
1551	CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7



#	ARTICLE	IF	CITATIONS
1552	Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. <i>Discover Oncology</i> , 2022, 13, .	0.8	13
1553	Advanced Cell Therapies for Glioblastoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1554	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
1555	Bioengineered immunomodulatory organelle targeted nanozymes for photodynamic immunometabolic therapy. <i>Journal of Controlled Release</i> , 2022, 350, 215-227.	4.8	6
1556	Nanoscale metal-organic framework-mediated immunogenic cell death boosting tumor immunotherapy. <i>Materials and Design</i> , 2022, 222, 111068.	3.3	3
1557	Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation. <i>Bioactive Materials</i> , 2023, 21, 57-68.	8.6	15
1558	On-demand integrated nano-engager converting cold tumors to hot via increased DNA damage and dual immune checkpoint inhibition. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1740-1754.	5.7	5
1559	Reprogramming dysfunctional dendritic cells by a versatile metabolism nano-intervenor for enhancing cancer combinatorial immunotherapy. <i>Nano Today</i> , 2022, 46, 101618.	6.2	5
1560	In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. <i>Biomaterials</i> , 2022, 289, 121808.	5.7	19
1561	Advances in mRNA Delivery and Clinical Applications. <i>RNA Technologies</i> , 2022, , 277-305.	0.2	0
1562	Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles. , 2022, , 9-39.		0
1563	Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation. <i>Journal of the American Chemical Society</i> , 2022, 144, 16366-16377.	6.6	23
1564	Toxoplasma gondii infection possibly reverses host immunosuppression to restrain tumor growth. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	5
1565	Nanocatalytic bacteria disintegration reverses immunosuppression of colorectal cancer. <i>National Science Review</i> , 2022, 9, .	4.6	14
1567	Applications of Covalent Organic Frameworks (COFs) in Oncotherapy. , 0, , .		1
1568	A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses. <i>Nature Communications</i> , 2022, 13, .	5.8	55
1569	Applications of Functional DNA Materials in Immunomodulatory Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 45079-45095.	4.0	9
1570	Manganese-Based Tumor Immunotherapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	42

#	ARTICLE	IF	CITATIONS
1571	Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2022, 74, 1146-1175.	7.1	8
1572	Guidelines for mouse and human DC generation. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	9
1573	Targeting FGL2 in glioma immunosuppression and malignant progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1574	Patient-Specific Mathematical Model of the Clear Cell Renal Cell Carcinoma Microenvironment. <i>Journal of Personalized Medicine</i> , 2022, 12, 1681.	1.1	3
1575	IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor. <i>Biology</i> , 2022, 11, 1575.	1.3	1
1576	Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance. <i>Cells</i> , 2022, 11, 3183.	1.8	11
1577	Narrative review on century of respiratory pandemics from Spanish flu to COVID-19 and impact of nanotechnology on COVID-19 diagnosis and immune system boosting. <i>Virology Journal</i> , 2022, 19, .	1.4	7
1578	A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2022, 11, 2079-2093.	1.3	11
1579	Regulation of epigenetic modifications in the head and neck tumour microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1580	The role of dendritic cells in neuroblastoma: Implications for immunotherapy. <i>Immunobiology</i> , 2022, 227, 152293.	0.8	3
1581	Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: A mathematical model. <i>Journal of Theoretical Biology</i> , 2023, 556, 111297.	0.8	2
1582	Single-component lipid nanoparticles for engineering SOCS1 gene-silenced dendritic cells to boost tumor immunotherapy. <i>Biomaterials Science</i> , 2022, 11, 263-277.	2.6	2
1583	Overexpression of lncRNA TUG1 enhances the efficacy of DC-CIK immunotherapy in neuroblastoma in vitro and in vivo. <i>Cancer Biomarkers</i> , 2022, , 1-9.	0.8	0
1584	Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 5438.	1.7	8
1585	FTIR microscopy evaluation of the immunogenicity of eco-friendly $\text{Fe}_2\text{O}_3@Ag@Cs$ nanocomposite as a platform for the discovery and screening of vaccine adjuvants. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2023, 287, 122087.	2.0	2
1586	Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model. <i>PLoS ONE</i> , 2022, 17, e0277248.	1.1	5
1587	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
1588	Cell penetrating peptide: A potent delivery system in vaccine development. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9

#	ARTICLE	IF	CITATIONS
1589	Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting. <i>International Immunopharmacology</i> , 2022, 113, 109434.	1.7	10
1590	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. <i>JAMA Oncology</i> , 2023, 9, 112.	3.4	133
1591	A macrophage membrane-coated mesoporous silica nanoplatforn inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy. <i>Journal of Controlled Release</i> , 2023, 353, 535-548.	4.8	10
1592	Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. <i>Investigative and Clinical Urology</i> , 2023, 64, 74.	1.0	3
1593	Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies. <i>Cancers</i> , 2022, 14, 4380.	1.7	10
1594	Evaluation and mechanism of immune enhancement effects of <i>Pleurotus ferulae</i> polysaccharides-gold nanoparticles. <i>International Journal of Biological Macromolecules</i> , 2023, 227, 1015-1026.	3.6	9
1595	A single-cell surgery microfluidic device for transplanting tumor cytoplasm into dendritic cells without nuclei mixing. <i>Biotechnology Journal</i> , 0, , 2200135.	1.8	0
1596	Diaphanous-related formin subfamily: Novel prognostic biomarkers and tumor microenvironment regulators for pancreatic adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	0
1597	A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 12474.	1.3	5
1599	Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect. <i>British Journal of Cancer</i> , 2023, 128, 715-725.	2.9	14
1600	Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1601	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 746-762.	0.5	0
1602	Attenuating Metabolic Competition of Tumor Cells for Favoring the Nutritional Demand of Immune Cells by a Branched Polymeric Drug Delivery System. <i>Advanced Materials</i> , 2023, 35, .	11.1	9
1603	Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages. <i>Experimental Dermatology</i> , 2023, 32, 290-296.	1.4	3
1604	Role of T cells in cancer immunotherapy: Opportunities and challenges. , 2023, 1, 116-126.		11
1605	Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency. <i>Genes</i> , 2022, 13, 2287.	1.0	5
1606	Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 279-294.	1.2	3
1607	Effects of Neuropeptides on Dendritic Cells in the Pathogenesis of Psoriasis. <i>Journal of Inflammation Research</i> , 0, Volume 16, 35-43.	1.6	1

#	ARTICLE	IF	CITATIONS
1608	Cellâ€Sized Lipid Vesicles as Artificial Antigenâ€Presenting Cells for Antigenâ€Specific T Cell Activation. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	5
1609	Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors. <i>ELife</i> , 0, 12, .	2.8	1
1610	Features of peritoneal dendritic cells in the development of endometriosis. <i>Reproductive Biology and Endocrinology</i> , 2023, 21, .	1.4	3
1611	Perioperative corticosteroid treatment impairs tumor-infiltrating dendritic cells in patients with newly diagnosed adult-type diffuse gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1612	Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity. <i>IScience</i> , 2023, 26, 105954.	1.9	4
1613	Dendritic cell-based immunity: Screening of dendritic cell subsets in breast cancer-bearing mice. <i>Journal of Microscopy and Ultrastructure</i> , 2023, .	0.1	0
1614	GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1615	Biomaterialâ€Based In Situ Cancer Vaccines. <i>Advanced Materials</i> , 0, , .	11.1	13
1616	Dendritic Cell-Based Cancer Immunotherapy. , 2023, , 1-28.		0
1617	Cancer vaccineâ€s multiverse and the future ahead. , 2022, , 335-360.		0
1618	Cancer immunotherapy via nucleic acid aptamers. , 2023, , 317-346.		0
1619	Recent Progress and Prospects of Immunotherapy in Multidrug-Resistant and Metastatic Breast Cancer Treatment. , 2023, , .		0
1620	Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies. <i>Advances in Cell and Gene Therapy</i> , 2023, 2023, 1-9.	0.6	2
1621	Vagus innervation in the gastrointestinal tumor: Current understanding and challenges. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188884.	3.3	2
1622	Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188869.	3.3	1
1623	Tumor-derived microparticles-based nanomaterial as platform for delivery of tumor antigens to enhance immunogenicity. <i>Chemical Engineering Journal</i> , 2023, 464, 142497.	6.6	1
1624	Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses. <i>Journal of Controlled Release</i> , 2023, 357, 310-318.	4.8	4
1625	Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?. <i>Cancer Letters</i> , 2023, 562, 216168.	3.2	7

#	ARTICLE	IF	CITATIONS
1626	Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114685.	2.5	9
1627	Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114377.	2.5	0
1629	Catalytically Active Metal-Organic Frameworks Elicit Robust Immune Response to Combination Chemodynamic and Checkpoint Blockade Immunotherapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 6442-6455.	4.0	8
1630	Liposomal Formulations of a Polylysine-Antigen Conjugate as Therapeutic Vaccines against Cervical Cancer. <i>Pharmaceutics</i> , 2023, 15, 602.	2.0	4
1631	A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis. <i>Nature Communications</i> , 2023, 14, .	5.8	25
1632	Nucleus-Targeting Manganese Dioxide Nanoparticles Coated with the Human Umbilical Cord Mesenchymal Stem Cell Membrane for Cancer Cell Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 10541-10553.	4.0	8
1633	A Fluorinated Supramolecular Self-Assembled Peptide as Nanovaccine Adjuvant for Enhanced Cancer Vaccine Therapy. <i>Small Methods</i> , 2023, 7, .	4.6	11
1634	Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy. <i>Nano Letters</i> , 2023, 23, 1904-1913.	4.5	9
1635	Analysis of approaches to increase the efficacy of cell therapy based on mesenchymal stromal cells. <i>Genes and Cells</i> , 2021, 16, 22-28.	0.2	0
1636	Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen. <i>International Immunopharmacology</i> , 2023, 117, 109887.	1.7	6
1637	The Renewal of Cancer Immunotherapy. <i>Vaccines</i> , 2023, 11, 592.	2.1	0
1638	Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer. <i>Cancers</i> , 2023, 15, 1626.	1.7	2
1639	Chemokines and Chemokine Receptors in Cancer: An Update. , 2023, , 1-30.		0
1640	Development of a Cancer Nanovaccine to Induce Antigen-specific Immune Responses Based on Large-Sized Porous Silica Nanoparticles. <i>ACS Applied Materials &amp; Interfaces</i> , 0, , .	4.0	2
1642	Vaccination with celecoxib-treated dendritic cells improved cellular immune responses in an animal breast cancer model. <i>Advances in Medical Sciences</i> , 2023, 68, 157-168.	0.9	0
1643	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6738.	1.8	5
1644	Application of Biomaterials in Cancer Research. <i>Biological and Medical Physics Series</i> , 2023, , 245-289.	0.3	0
1645	Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
1646	Microfluidic Chips: Emerging Technologies for Adoptive Cell Immunotherapy. <i>Micromachines</i> , 2023, 14, 877.	1.4	2
1647	Inducible nitric oxide synthase 2 (NOS2) and antitumor $\hat{I}^3\hat{I}$ -T cells. , 2023, , 151-172.		0
1650	Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy. <i>ACS Nano</i> , 2023, 17, 9826-9849.	7.3	9
1654	HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. <i>VirusDisease</i> , 2023, 34, 172-190.	1.0	3
1655	Dendritic cells and glioblastoma. , 2023, , 515-538.		0
1659	Immunology and immunotherapy in gastric cancer. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3189-3204.	1.9	1
1672	Metal-based drug delivery systems for cancer immunotherapy. , 2023, , 851-891.		0
1682	Emerging Vaccine for the Treatment of Cancer via Nanotechnology. , 2023, , 227-244.		0
1687	Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	6
1692	Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy. <i>Methods in Cell Biology</i> , 2023, , .	0.5	0
1716	Dendritic cell therapy for neurospagioma: Immunomodulation mediated by tumor vaccine. <i>Cell Death Discovery</i> , 2024, 10, .	2.0	0
1725	Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators. <i>Cancer Immunology, Immunotherapy</i> , 2024, 73, .	2.0	0